Doctor of Philosophy by Wu, Chun-Jen




A dissertation submitted to the faculty of 
The University of Utah 
in partial fulfillment of the requirements for the degree of
Doctor of Philosophy
Department of Materials Science and Engineering 
The University o f Utah 
December 2013
Copyright © Chun-Jen Wu 2013 
All Rights Reserved
T h e  U n i v e r s i t y  o f  U t a h  G r a d u a t e  S c h o o l
STATEMENT OF DISSERTATION APPROVAL
The dissertation of Chun-Jen Wu
has been approved by the following supervisory committee members:
Agnes Ostafin , Chair 10/24/2013
Date Approved
John Morrison Veranth , Member 10/28/2013
Date Approved
Ling Zang , Member 10/24/2013
Date Approved
Ashutosh Tiwari , Member 10/31/2013
Date Approved
Jennifer Shumaker-Parry , Member 10/24/2013
Date Approved
and by Feng Liu
the Department of
, Chair of
Materials Science and Engineering
and by David B. Kieda, Dean of The Graduate School.
ABSTRACT
In this dissertation, the surface coating method/characteristics and a novel synthesis 
method for perfluorocarbon (PFC) emulsions were studied. These materials have relevance 
in a wide range of industrial and biomedical areas. Electrostatic coating of emulsions with 
poly-L-lysine (PLL) and chitosan (CS) was used to enhance the stability of the emulsions 
against phase separation. The ionic surfactant, 1,2-dioleoyl-sn-glycero-3-phosphate, DOPA, 
was used as an additive to the nonionic surfactant lecithin in order to increase the surface 
charge of the emulsion surface and facilitate accumulation of coating materials on the 
emulsion surface. Analysis of zeta potential versus pH was used to establish the best 
conditions for the coating process. The particle size and zeta potential was used to follow 
the coating progress. To characterize the final product, colorimetric determination was 
used to measure the bound/unbound fraction of PLL and CS and this was compared with a 
model-based analysis of zeta potential as a function of coating. Through this comparison 
and accounting for experimental error, a discrepancy in the effective particle number was 
revealed that was interpreted in terms of the compression and expansion of coating 
molecules on the surface as it assembles. Fluorescence quenching measurements using 
pyrene and fluorescein-doped emulsions supported the compression/expansion concept, 
resulting in more quenching when expansion of the coating took place. Thermodynamic 
analysis also supported these conformation changes and indicated a lowering of surface 
free energy for expanded coating.
The second part of the dissertation reports a novel cosolvent method to synthesize 
PFOB emulsion with high yield production, in contrast to traditional extrusion methods 
that generate a large amount of water-filled liposomes as a side product. It was found that 
the selection of best cosolvent is related to its polarity relative to that of perfluorooctyl 
bromide (PFOB). Fourier transform infrared spectroscopy (FTIR) analyses were used to 
measure the retention of PFOB and revealed that nonpolar hexane has the best PFOB 
retention ability compared to methanol, ethanol, and chloroform. Moreover, phase 
transition temperatures (PTT) of the hexane/PFOB/lecithin system were observed at 
13~19 °C and 22~24 °C by monitoring both the change in transparency by UV-Vis 
spectrophotometry and PFOB retention by FTIR. If emulsions are produced above the PTT 
(at 30 oC), PFOB is not retained. Quantitative measurement using FTIR for the best 
conditions gave 72% PFOB retention using the cosolvent method. Fluorescent and density 
analysis by centrifugation indicated that the traditional method for emulsion synthesis 
(directly emulsified) produced significantly more low-density water-filled liposomes than 
the cosolvent method. Higher density PFOB emulsion made with the cosolvent method can 
be easily separated and concentrated by centrifugation. The image of emulsions made by 
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For several decades, blood substitutes have enjoyed generous investment and intensive 
research. Although blood transfusion is still the mainstream clinical treatment, there are 
some unavoidable issues like limited lifetime of blood storage (35 to 42 days, at 2-6 °C), 
shortage during emergency demand (war, trauma, and disaster), and blood donations 
declining for all types of blood [1]. A side-effect of transfusion is that recipients could 
experience reduced immune response, so-called immunosuppressive effect [2-4]. Another 
critical issue is that blood transfusion still has the potential risk of blood-borne disease such 
as hepatitis C [5], HIV [6], Cruetzfeld-Jacob [7], and SARS [8]. Hence, blood substitutes 
in the form of synthetic nonhuman/animal materials are vital and necessary for the future 
welfare of humans to meet the acute need for blood transfusion [9].
The first development of blood substitutes dates back to the early 1600s when sheep’s 
blood was transfused to the wounded soldiers [10]. After that, ale, wine, and opium were 
attempted in the mid-1600s [11]. In the 19th century, milk from cows, goats, and humans 
was used as well [12]. Of course, these blood substitutes did not work well due to severe 
reactions. Until 1949, an experimental hemoglobin saline solution was used to treat
patients with postpartum hemorrhage after exhausting available compatible banked blood, 
but the patients died due to renal failure [13]. It was reported in 1966 that mice immersed 
in perfluorocarbon liquid saturated with oxygen could survive up to 10 min [14]. The idea 
of polymerized hemoglobin-based oxygen carriers (HBOCs) was first proposed in 1978 to 
avoid the serious systemic toxicity problems when stroma-free hemoglobin solution is 
infused into patients [15]. Although not available commercially, perfluorocarbons (PFCs) 
and hemoglobin-based oxygen carriers remain the two main blood substitute candidates 
[16-18].
Schmidt revisited perfluorocarbon as the base material on which to design a blood 
substitute, coating it with an inorganic rigid layer [19-23], but since then, our research 
group has encountered problems in the production and stability. The focus of this work is 
to produce a reinforced, perfluorocarbon-based blood substitute using layer-by-layer 
deposition of biological polymers at high reaction yields. The challenges in this area 
include: 1) poor understanding of the relation of polymer structure to emulsion phase 
stability, 2) dynamic changes of the conformation of lipids/polymers on the emulsion 
surface and how it affects gas exchange and interactions with other molecules in the blood, 
and 3) how to produce materials with high yield.
In this project, we focus on two issues: 1) how to characterize the emulsion coating 
process and characteristics of the coating, and 2) how to produce high yield of emulsion.
For the first issue, we chose two different molecules, poly-L-lysine (PLL) and chitosan, 
to coat the surface emulsion. Both molecules have the ability to modulate their surface 
charges for layer-by-layer deposition via pH titration due to amino acids in PLL and amine 
groups in chitosan. In this thesis, PLL with molecular weight between 500~2000 and
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chitosan with molecular weight 150,000 were used for emulsion coating. PLL and chitosan 
have 8.6 and 837.2 repeat units in their structure so it can be expected that PLL is a short- 
chain molecule and chitosan is a long-chain molecule.
We developed a method to characterize the process of coating of an emulsion with PLL 
and chitosan that utilized a combination of calculation and zeta potential measurement, and 
used it to quantify the degree of emulsion coating and the properties of the coating at 
various time points in the coating process. For the second issue, we demonstrate an 
improvement in production efficacy of emulsion using a method of cosolvent addition. The 
concept has been tried in other emulsion systems [24, 25], but not reported in the literature 
for perfluorocarbon-based systems.
This work should be helpful for the synthesis and further development of the 
perfluorocarbon-based system as an artificial oxygen carrier (AOC). In addition, it is a new 
approach for the study and prediction of the conformation of polymeric coating materials 
on emulsions and other microparticles. This is important in the design of drug delivery 
particles and active thin film coatings. The cosolvent method could be used to synthesize at 
high yield a variety of oil-in-water (O/W) systems for drug delivery, cosmetics, and food 
industry.
1.2 Background
1.2.1 Blood substitutes: HBOCs and PFCs 
HBOC production starts from purified cell-free hemoglobin (Hb), which is derived 
from human or animal blood by lysing red blood cells (RBCs) and removing pieces of cell 
membrane and other proteins [26]. Cell-free Hb, also called stroma-free hemoglobin
3
(SFHb), is supposed to have no antigenicity, better immunologic and allergic responses 
compared to RBC, and a prolonged lifetime [27, 28]. However, it needs modification to 
express similar properties as Hb still inside in RBCs because outside the cell, SFHb shows 
irreversible high oxygen affinity, contributes to elevated oncotic pressure via reaction with 
NO, and experiences rapid intravascular clearance, thus reducing its duty time [26, 27]. 
Modified SFHb can fix some of these issues but still has serious problems of renal toxicity 
[27, 29, 30], hypertension and vasoconstriction [31-33], gastrointestinal distress [32, 34], 
neurotoxicity [35-37], free radicals [38-40], and platelet and coagulation effects [41-43]. 
HBOCs that have made it to various stages of clinical trials include poly-SFHb-P 
(PolyHeme®) [44, 45], HBOC-201 (Hemopure®) [46-48], rHb1.1 and rHb2.0 (OptroTM) 
[49-51], Hb-raffimer (HemoLink™) [52, 53], and DCLHb (HemoAssist™) [54, 55]. 
Although these products have excellent oxygen affinity and shelf time, they still have many 
obstacles to overcome in order to be a safe and effective HBOC product [26].
Perfluorocarbons (PFCs), another candidate for blood substitutes, are derived from 
hydrocarbons by replacing all the hydrogen atoms with the fluorine atoms. PFCs used as an 
HBOC are colorless liquids with high density (usually up to twice that of water) and low 
viscosity (due to low intermolecular attraction forces). The first PFCs were developed as a 
part of Manhattan project during War World II to use as an insulating material [56]. In 
mid-1960, it was later discovered that the synthetic PFCs could dissolve and transport a 
large quantity of nonpolar gas such as nitrogen and oxygen [57, 58]. Due to the strongest 
carbon fluorine bond in organic compound, PFCs are inert and fairly chemically stable in 
human body, suggesting they should be quite safe for blood substitutes [59]. However, 
PFCs cannot be used directly since they are immiscible with aqueous solutions, like plasma.
4
Emulsification before introduction into blood stream is necessary. Fluosol® was the first 
approved PFC-based artificial blood substitute by the US Food and Drug Administration 
(FDA) [16, 60]. Details about related PFC products will be illustrated more in Section of
1.2.2.
In this study, PFCs were used as the starting point of blood substitutes because they are 
much less toxic than HBOCs.
1.2.2 Perfluorocarbon-based products
Many biomedical applications for PFCs can be listed, such as anticancer agents [61-63], 
perfusates for isolated organs [64], cell culture media supplements [65, 66], liquid 
ventilation fluids [14, 67, 68], surgery tools in ophthalmology [69, 70], and diagnostic 
imaging agents [71-73]. In this section, perfluorocarbon-based products utilized mainly for 
blood substitutes are listed and discussed in greater detail.
For the first generation of PFC emulsion, Fluosol® by Green Gross, Japan was the first 
proposed commercially in 1989 and approved by FDA [16]. It was originally used 
clinically as an oxygen-carrying adjunct to coronary balloon angioplasty for patients with 
high risk. This product ceased production in 1994 for economic reasons as it was seldom 
used by cardiologists during angioplasty [74]. Other limitations of Fluosol® included 
storage problem (unstable in room temperature), relatively poor O2 carrier efficacy 
(compared to hemoglobin), and activation of Pluronic F68 by the complement system 
activating and altering white blood cell function. Another product Oxypherol also from 
Green Gross, Japan was not used clinically due to long retention half time (> 500 days) of 
PFC in the human body [75]. Perftoran®, produced in Russia, is used as a temporary
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intravascular oxygen carrier for haemorrhagic shock patients and perfusate for isolated 
human organs from Russia was approved in 1995-1996 by the Russian health regulatory 
authorities [76].
The second generation of PFC emulsion was improved by focusing on biocompatibility 
and excretion in the human body via the molecular weight selection of PFCs, prolonging 
the shelf-life by adding perfluorinated stabilizers and surfactants, and manufacturing 
concentrated emulsions with larger PFC molecules but with lower viscosity [75, 77]. 
OxygentTM, with 4 days o f retention half time proposed from USA, can be stored more 
than one year at 5 to 10 °C and it has completed phase III in Europe, May 2000 [75, 78-80]. 
Similarly, OxyfluorTM with added safflower oil and egg yolk phospholipids as the stabilizer 
and surfactants was developed in USA [81-83]. For now, it mainly has been the 
commercial product as an oxygen scavenging enzyme [84-86]. Other products like Fluxon 
and Oxycyte® (Oxygen Biotherapeutics, Inc.) were also synthesized for the improvement 
of the stability or appropriate retention half time [75, 87, 88]. However, the current status 
of Fluxon is not clear. As for Oxycyte®, it is approved currently for phase II-b trials in the 
United States, and for phase II-b clinical trials in Switzerland and Israel for use in treating 
traumatic brain injury (TBI) [89, 90]. It has been targeted as an oxygen therapeutic rather 
than a blood substitutes [91].
1.2.3 PFC candidate - perfluorooctyl bromide (PFOB)
The development of second-generation PFC emulsions in the West described in the 
previous section has focused on linear perfluorocarbon molecules such as perfluorooctyl 
bromide (C8F17Br) or perfluorodecyl bromide (C10F21Br) [75, 78-80]. In this dissertation,
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perfluorooctyl bromide (PFOB), also referred to as 1-bromoperfluorooctane and perflubron, 
was chosen for the following research. The principal consideration for the selection of this 
PFC relates to its retention half time in human body and its efficacy of oxygen solubility 
and delivery.
The organ retention half time of PFCs in human body primarily depends on the 
molecular weight, and molecular structure and the presence of heteroatoms or cycles have 
minimal influence [92]. It is usually acceptable for PFCs with molecular weight around 
460 to 500 g/mol, which have organ retention half time around 10 to 50 days [93]. From 
animal studies, the retention half time of PFOB (molecular weight: 499 g/mol) is 
approximately 4 days [93, 94]. Then, PFOB becomes vapor gradually and leaves from the 
human body through the lung [95]. PFOB can be manufactured with a high degree of 
purity, which means unwanted side products can be avoided. In the past, physiological side 
effects have often been attributed to partially fluorinated contaminants [96]. Compared to 
perfluoro-2-methyloctane, perfluoro-2-methyl-3-isopropylpentane, perfluorodecane, 
perfluoro-2,7-dimethyloctane, 1-bromoperfluorohexane, 1-bromoperfluoroheptane, 1- 
bromoperfluorodecane, 1-iodoperfluorodecane, and perfluorotributylamine (FC-47), PFOB 
shows excellent values of oxygen capacity in room air (1.0 ± 0.4 ml O2/100ml emulsion) 
and saturated with 97% O2 / 3% CO2 (5.3 ± 0.2 ml O2/100ml emulsion) as it was 
emulsified by a nonionic surfactant, Pluoronic® F-68 [97]. The terminal bromine atom on 
the PFOB molecule confers relative lipophilicity, which improves its ability to be 
emulsified by surfactants [98, 99]. Hence, this is the reason that PFOB could be an 
excellent candidate in this work.
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1.2.4 PFOB emulsion and colloidal system 
Due to their high lipophilicity, surfactants are necessary to emulsify PFOB so it can be 
used in an aqueous system for biomedical applications. As a second-generation injectable 
blood substitute, egg yolk phospholipids (EYP) were successfully utilized to emulsify 
perfluorocarbon [81-83]. From thermodynamics, an emulsion is an unstable system 
because of Ostwald ripening, which is the basic mechanism by which small droplets grow 
into large droplets through the process of molecular diffusion [100-102]. During the 
process, small PFOB droplets diffuse through the continuous aqueous phase toward large 
droplets at the expense of the former [103]. For this reason, emulsions usually have a 
storage problem at room temperature. Some reports related to the second-generation PFC 
emulsions show that a small amount of additive can significantly retard the process of 
Ostwald ripening [75, 77, 104]. In this work, PFOB was emulsified by surfactants and 
coated with additional molecules. This should also reduce the possibility of Ostwald 
ripening, in addition to reinforcing the mechanical stability of the particle. Details about 
emulsion coating will be illustrated later.
The main emulsification lipids used for biomedical applications are phospholipids. 
They have components of one hydrophilic head group and one or two hydrophobic tails. 
Once the surfactants are in the boundary of oil and water, the tails insert into oil and the 
head group orients toward the water. Once equilibrium has been reached, the interfacial 
tension between two liquids is lowered and the surfaces in this system experience less 
driving force to change, so the system is stable. The geometry or structure of the emulsion 
particles is strongly dependent on the amount and structure of the emulsifier, temperature, 
and presence of impurities. As surfactants (or lipids) are added in increasing amount into
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an emulsion, different phases such as reverse emulsions, liposomes, micelles, and reverse 
micelles can be formed [105-107] (Figure 1.1).
To use PFOB emulsions as a blood substitute, an oil-in-water (O/W) emulsion with 
highest volume of PFOB is desired, as shown in Figure 1.1 (a). In Figure 1.1 (d), a micelle 
with limited diameter around 20 nm can only carry a small amount of PFOB. If the ratio of 
oil to water increases to a certain level, the oil-in-water emulsion tends to become water-in- 
oil emulsion, shown in Figure 1.1 (b), doing so by passing through a complex bicontinuous 
phase. In some situations, reverse micelles in Figure 1.1 (e) would form in the oil-in-water 
system. Liposomes are sometimes generated in the system of oil, water, and surfactant 
because of the presence of extra surfactant in water relative to the oil. Liposomes are 
usually synthesized by adding lipid in water [108-110],
Figure 1.1 The structures of various colloid systems: (a) oil-in-water (O/W) emulsion, (b) 
water-in-oil (W/O) emulsion, (c) liposomes, (d) micelle, and (e) reverse micelle
1.2.5 The other biomedical applications of PFOB emulsion
In this section, other biomedical applications of PFOB emulsions (except for blood 
substitutes or high oxygen capacity related applications such as perfusates for isolated 
organs, cell culture media supplements, liquid ventilation fluids, and surgery tools in 
ophthalmology) are introduced.
1.2.5.1 Contrast agents for ultrasound imaging
In order to use ultrasound in diagnosis, a good sound reflector should be used. The 
optimal reflector, or contrast agent, for ultrasound are tiny gas bubbles, that can be highly 
compressed by the sound waves [111-113]. The key to good contrast is that the bubble 
compress much more (absorbing more energy) than the surroundings that may contain cells 
such as red blood cells. However, there are no ideal injectable gas bubbles because the 
diameter of bubbles cannot be controlled and the circulation time is not be long enough for 
imaging (the air in gas bubbles tends to diffuse out due to the combination of surface 
tension (Laplace pressure) and blood pressure). For osmotic stabilization, the partial vapor 
pressure of PFC can be applied in gas bubble to counterbalance the surface tension and 
blood pressure so osmotic stabilization in gas bubbles can be achieved [73, 114, 115]. 
Imavist™ has been developed as an ultrasound contrast agent based on PFOB emulsion 
[116, 117].
1.2.5.2 Contrast agents for magnetic resonance imaging (MRI)
For MRI, superparamagnetic iron oxide nanoparticles (SIONs) with high sensitivity are 
used widely, but they cannot be detected directly, so excretion and tissue retention can
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deplete MRI signal in the human blood stream to influence the final result of imaging [118­
120]. It would be very difficult to interpret if darker areas are from nanoparticles or from 
other inhomogeneities by anatomic proton (1H) MRI [119]. PFC can be used alternatively 
as an MRI contrast agent because of the presence of its natural fluorine isotope 19F, which 
has similar sensitivity to 1H [121, 122]. Basically, 19F has 100 % natural abundance 
because no other isotopes exist in significant quantities due to their unstable property [123]. 
The lack of 19F background in the human body results in high imaging specificity. This 
isotope can also be applied to measure tissue oxygen tension and to map oxygen in tissue 
via the ability of nearby paramagnetic oxygen molecules (O2) to perturb the signal of 19F 
MRI [124, 125]. In various reports, myocardial vascular volume [126], local cerebral 
volume [127], and tumor imaging [128] were studied by utilizing PFC contrast agents for 
19F MRI.
1.2.5.3 Contrast agents for computed tomography (CT) and sonography
PFOB can be used as a contrast agent in CT because it is radiopaque [129]. Thus, it has 
the unique ability to enhance the signal of blood vasculature, whereas other contrast agents 
only enhance imaging of the liver and spleen [130, 131]. This is because PFOB emulsions 
introduced by IV injection, unlike water-soluble contrast media, do not diffuse into the 
interstitial space. This can prolong the circulation time in blood vasculature since it is less 
likely to be filtered by the kidneys [132]. Due to the limitations of water-soluble contrast 
enhancers, PFC emulsion is a potential substitute [133].
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1.3 Emulsion manufacture and challenges
1.3.1 Introduction of homogenizers 
It is essential to add a surfactant in order to emulsify PFOB in aqueous solution. To 
acquire a uniform emulsion consisting of specifically-sized particles homogenization, using 
intense mechanical agitation is needed [134, 135]. There are several types of homogenizers 
such as high-speed blender, high-pressure homogenizer, colloid mill, high shear disperser, 
ultrasonic disruptor, and membrane homogenizer [136, 137]. A high-speed blender with a 
stirring vessel is fairly inexpensive, so it is widely used for synthesis or mixing [138-140]. 
A broad size distribution and large particle size of the products results, therefore, a high­
speed blender usually is used for the premix production. A high-pressure homogenizer is 
the most commonly used method for producing fine (submicron) emulsions in food 
industry [141]. In this device, the emulsions collapse into smaller ones as coarse emulsions 
enter into the homogenizer valve and eject from the exit [142]. This technique also has 
been used extensively for emulsion manufacture [143-145]. A colloid mill is used in the 
food industry to make emulsions with medium or high viscosity [146]. Emulsion rather 
than the separate oil and aqueous solution is fed into a narrow channel between the rotor (a 
rotating disk) and the stator (a static disk). The shear stress in the channel can reduce the 
particle size of the emulsion [134, 147]. The emulsion size can be controlled by the speed 
of the rotor and the thickness of the channel. The basic design principal of a high shear 
disperser is similar with a colloid mill, which both have the system of rotor and stator [148]. 
The coaxial intermeshing rings with radial openings in a high shear disperser could 
generate high shear forces and turbulent flow to disrupt the emulsion into smaller droplets 
[149]. An ultrasonic disruptor used sound waves exceeding a frequency of 20k Hz that is
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generated by piezo-electric or magneto-restrictive transducers. The generated waves could 
disrupt the emulsion by inducing cavitation in which smaller local pressure is less than the 
vapor pressure of the solvent [150, 151]. A membrane homogenizer can produce narrow 
particle size distribution of the emulsion by pushing the disperse phase or emulsion 
through the microporous membrane against high pressure [152, 153]. This process is called 
extrusion, and the resulting particle size mainly depends on the membrane pore size, 
applied pressure, and materials. For high dispersed phase concentrations, recirculation 
could make it a time-consuming process. In this study, membrane homogenization (or 
extrusion) is the preferred method to homogenize PFOB emulsion for a smaller size and a 
narrow size distribution.
1.3.2 Selection of surfactants 
Typically, surfactants have one hydrophilic side called a head group and one 
hydrophobic or lipophilic side called a tail. Most surfactants have similar tails made of 
linear, branch, or aromatic hydrocarbons and usually have either one or two tails in their 
structure. Hence, most surfactants could be classified into various types by means of their 
polar head groups, such as nonionic surfactant, ionic surfactant (anionic and cationic 
surfactant), and zwitterionic surfactant [154]. Because the coating of the emulsion by 
electrostatic forces will be conducted for our emulsion design, ionic surfactants can 
provide more surface net charges for coating than the nonionic one in this work. However, 
charge lipids are general more expensive than neutral lipids, and the cost considerations of 
large-scale emulsion manufacture suggested that the combination of ionic and non-ionic 
surfactants may be preferred. The nonionic surfactant, L-a-phosphatidylcholine (lecithin),
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and anionic surfactant, 1,2-dioleoyl-sn-glycero-3-phosphate (sodium salt) (DOPA), were 
used in this work. In eukaryotic cells, phosphatidylcholine (lecithin) is the major 
phospholipids in cell membrane [155-157], which serves as a reservoir of several lipid 
messengers [158]. The toxicity of lecithin was reviewed in previous studies, and it has been 
applied in many biomedical applications such as drug delivery, gene delivery, vaccination, 
diagnosis, and so on [159-163]. In addition, lecithin from soy has huge potential for large- 
scale production owing to its low cost and large production volume. DOPA is a synthetic 
phospholipid that could provide highly negative charge at most working pH, but it is 
expensive. Only a small amount was used to improve the surface potential of lecithin 
emulsion by integrating it with lecithin.
1.3.3 The challenge of emulsion manufacture
Emulsions may be transiently or permanently stabile. The kind of surfactant is the 
ingredient that leads to the formation of an ideal, stable, and uniform emulsion from the oil 
and aqueous solution. However, depending on the thermodynamics of the system, the 
emulsion could break completely (known as coalescence) and form two separated layers of 
oil and water solutions during a period of time. This process could occur by four possible 
mechanisms such as creaming, Brownian/sedimentation flocculation, and 
disproportionation [164-168]. The first three are primary mechanisms that destabilize 
emulsion and all the four mechanisms could occur simultaneously and in any order [169, 
170].
During the process of creaming, the emulsion does not actually break but instead there 
is a separation of the emulsion into two emulsions, each of which have a different ratio of
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oil to aqueous solution. Creaming, typically the precursor to coalescence, is the main 
process to form a disperse phase separated from an emulsion. According to Stoke’s 
equation, creaming is caused mainly by the density difference of oil and aqueous solution 
[166, 171, 172]. The equation can be shown:
u = 2 r2 (p -  P0) g / 9 n (1.1)
where
u is the creaming (setting) rate,
r is the emulsion radius,
p is the density o f emulsion,
p0 is the density o f dispersion medium,
g is the acceleration of gravity,
n is the viscosity of dispersion medium
From the above equation, it is clear that the creaming rate is reduced for small radius 
size emulsions, small density differences between oil and aqueous materials, and high 
viscosity. For biomedical applications of PFOB emulsion, a small particle size is desired, 
but high viscosity of emulsion suspension should be avoided. The large density difference 
between PFOB and water is unavoidable. So the stability of PFOB emulsions against 
creaming could be a challenge for two out o f three reasons.
Flocculation generally is defined as the aggregation of emulsions. Emulsions can keep 
their integrity without coalescence, but they can attract each other to form clusters by 
various mechanisms such as Van der Waals forces [173, 174]. Separately, Brownian
flocculation is viewed as random movement of emulsions and sedimentation flocculation is 
viewed as vertical movement. Both flocculations occur simultaneously in an emulsion and 
the behaviors can be expressed by the following equation [175],
r  max = 2 n (p -  P0 ) g r4 / 3 kb T (1.2)
where
r max is the relative rate of each type of flocculation,
p is the density of emulsion,
p0 is the density of dispersion medium,
g is the acceleration of gravity,
r is the emulsion radius,
kb is Boltzmann constant,
T is absolute temperature (Kelvin)
If the value of r max > 10, Brownian flocculation can be negligible. If the value of r max < 
0.1, sedimentation aggregation is negligible. A simple calculation can be done by applying 
p = 1.93 g/ml (PFOB), p0 = 1 g/ml (water), g = 9.8 m/s2, r = 200 nm, and T = 300K. The 
value of relative rate for flocculation is then around 7.4 x 10-3, which means there should 
be Brownian flocculation, but no sedimentation aggregation. It should have some influence 
for the stability of emulsion by Brownian flocculation.
Disproportionation is a process related to Ostwald ripening. Smaller emulsions tend to 
diffuse toward and mix with larger emulsions at the expense of smaller emulsions due to
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the vapor pressure difference of large and small emulsion. The difference in pressure 
provides the driving force, shown by the Kelvin equation [176, 177],
where
P0 is the vapor pressure of the dispersion medium,
P is the vapor pressure of emulsion,
Y is the surface tension of the dispersion medium,
Vm is the molar volume of the disperse phase, 
r is the emulsion radius,
R is gas constant,
T is absolute temperature (Kelvin)
From the Stokes-Einstein equation, the diffusion rate (D) depends on the viscosity of 
the disperse phase and the particle size of emulsion [178, 179]. It can be shown as the 
following:
ln ( P0 / P ) = 2 y Vm / r R T (13)
(14)
where
kb is Boltzmann constant,
T is absolute temperature (Kelvin),
n is the viscosity of dispersion medium,
r is the emulsion radius
For the PFOB emulsions we are trying to produce, the viscosity of the dispersion 
medium cannot be too high [180] and the particle size should be around hundred 
nanometers. This means the Ostwald ripening diffusion rate between emulsion particles 
could be relative high.
A final challenge of emulsion manufacture is that liposomes could be accidentally 
generated during the emulsion production. It is inevitable to have liposomes by the method 
of blending oil, aqueous solution, and surfactants [181, 182].
1.4 Design of coating on emulsion surface
1.4.1 Overview: Why is coating necessary?
The purpose of emulsion coating can be listed as the enhancement of emulsion 
structure strength, the reduced possibility of biological removal and blood vessel 
penetration (the increment of blood circulation period), and the feasibility of other 
biomedical applications. It will be introduced in the following section.
1.4.1.1 The enhancement of emulsion structure strength
In the previous section, creaming, Brownian/sedimentation flocculation, and 
disproportionation (Ostwald ripening) could worsen the stability of the emulsion especially 
in fluid shearing conditions [183]. Many studies have reported that the shear stress in 
human blood vessel is relatively high [184-189]. Based on hemodynamics, laminar shear 
stress of blood vessel is normally about 2.5~46 dyn/cm2 [190, 191]. Thus injected PFOB 
emulsions could be easily destroyed or disrupted during blood circulation.
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1.4.1.2 The increment of blood circulation period
Emulsion size is another critical issue to point out. Because the smallest diameter of 
vascular capillaries in body is ~4 p,m [192], emulsions that are very large or flocculate 
significantly could be dangerous because they may be retained/caught by the capillary bed 
of the lungs [193, 194]. Moreover, macrophages of the mononuclear phagocytosis system 
(MPS) will try to immediately eliminate intravenously administered emulsions because 
they are recognized as foreign in the human body [195-197]. However, if the particles are 
smaller than 4 p,m, they are instead eliminated quickly by cells of the reticuloendothelial 
system (RES) [193, 195]. The RES can capture particles, like 60~90 % particles taken up 
by in the liver and 3~10 % particles by macrophages in the spleen [198-200]. It is often 
said that particles up to 100 nm would be phagocytosed by Kupffer cells and particles 
larger than 200 nm tend to be filtered by spleen [201]. If particles applied intravenously 
have size between 30 and 100 nm, larger particles tend to be eliminated faster from 
bloodstream than the smaller ones. Therefore, the larger the particle is, the shorter is its 
bloodstream half-life period [202].
Because of premature, size-dependent removal by the body’s defenses, only part of the 
administered particles can even reach target cells and tissues by blood circulation. Another 
bottleneck is the permeability of the vascular capillary wall [203]. There are four types of 
blood capillaries: tight junction capillaries (such as the blood brain barrier, BBB), 
continuous capillaries, fenestrated capillaries, and sinusoid capillaries. Tight junction 
capillaries with connection of their endothelial lining cells, in the central nervous system, 
are usually hard to penetrate [204, 205]. Continuous capillaries, in major tissues like 
muscle, skin, lung, and connective tissue, have a limitation for permeation, generally < 6
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nm in diameter [206, 207]. Larger particles (50~60 nm) can be excreted from the kidney 
through its fenestrated capillaries [208, 209]. If particles are larger than 60 nm, they only 
can be cleared by reticuloendothelial system (RES), which has sinusoid capillaries [210, 
211]. These capillaries have usually over 100 nm pores, witch are classified as the open 
pore capillary.
The particle size of PFOB emulsion should be designed for the desired purpose and 
duration of use, and remain mainly in blood circulation. In this study, biomaterials coated 
on emulsion surface for protection were designed to improve the structure strength of the 
emulsion particles. Besides, coating materials on emulsion surface can provide steric 
stabilization away from cell absorption such as the elimination of macrophages [212, 213].
1.4.1.3 The feasibility of other biomedical applications
The advantage of coating materials on the PFC emulsion is that the new surface can be 
tailored for specific biomedical applications like anticancer agents [61-63], tissue 
engineering [214-217], and drug or gene delivery [80, 218-222]. The new emulsion surface 
could be designed to improve biocompatibility, increase the dispersion in water, and 
prolong the circulation time in the blood stream by avoiding protein absorption or 
macrophage elimination. For the purpose of binding applications, the coated PFC emulsion 
also can be conjugated to itself or coated with ligands/receptors that can perform specific 
targeting. Hence, coating of an emulsion surface not only improves emulsion stability but 
also creates more biomedical opportunities.
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1.4.2 Coating materials 
In this study, two biomaterials, poly-L-lysine (PLL) and chitosan, were chosen for 
coating of the PFOB emulsion surface. PLL has charged lysine amino acids and chitosan 
has amine groups in their molecular structures so each would have net positive charge as 
pH is lowered and net negative charge as pH is raised. Having these molecules on the 
surface provides a means for us to control the surface charge or zeta potential of emulsion 
particles by pH titration.
1.4.2.1 Polylysine (PLL)
Lysine is the essential a-amino acid for human with the chemical formula 
HO2 CCH(NH2)(CH2) 4NH2. Lysines have two types of stereoisomers: L-lysine and D- 
lysine. Synthetic D-lysine can be converted from L-lysine [223, 224], which is rich in 
nature. In this work, poly-L-lysine (PLL) was used for one of coating materials on 
emulsion surface. The chemical structure of PLL is shown in Figure 1.2. Due to amine 
groups in the structure, the positive or negative charge of PLL would be adjusted by pH 
titration. If emulsion surface has the opposite electrical charge to that of the coating 
material, the coating process would be achieved by electrostatic attraction forces.
PLL has been used in various applications. It is usually applied as a food preservative 
owing to its low cytotoxicity [225-228]. Polylysine has the ability to inhibit the 
microorganism growth, and can also generate antimicrobial activity, specifically against 
yeast, fungi, and bacteria [229]. In January 2004, polylysine was certified as “generally 
recognized as safe” (GRAS) in United States [230, 231]. It also has been widely used as 
the capsules of the vehicles for gene delivery due to its ability to bind to negatively charged
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Figure 1.2 The chemical structure of poly-L-lysine. Adapted from Sigma-Aldrich. 
http://www.sigmaaldrich.com/catalog/product/sigma/p8954?lang=en&region=US
DNA [232-235]. PLL with the excellent biodegradability can also be utilized as the 
scaffold in tissue engineering [236-241], as well as polymer capsules or carriers in drug 
delivery [236, 242-244].
1.4.2.2 Chitosan
Glucosamine, which is an amino sugar with chemical formula C6H13NO5, is part of the 
structure of polysaccharide chitosan. It is found in the exoskeletons of crustaceans and 
other arthropods, cell walls in fungi, and other higher organism [245, 246]. The amine 
groups in its chemical structure take on positive charge at lower pH and negative charge at 
higher pH. It is similar to PLL in that tunable net electric charge of chitosan would be 
convenient to tune the process of electrostatic emulsion coating. The chemical structure of 
chitosan is shown in Figure 1.3.
Chitosan has also been used in various areas such as the automobile industry [247, 248], 
wastewater treatment [249-251], health care [252-254], and agriculture and horticulture 
[255, 256]. One of the more famous biomedical applications of chitosan is to use it as a
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Figure 1.3 The chemical structure of chitosan. Adapted from Sigma-Aldrich. 
http://www.sigmaaldrich.com/catalog/product/aldrich/740500?lang=en&region=US
hemostatic, mixing chitosan salt with organic acids like succinic or lactic acid [257-261]. 
Numerous biomedical applications like formation of hydrogels [262, 263], bio-composites 
[264, 265], or scaffolds for tissue engineering [266-269] were reported. It is characterized 
by biocompatibility, biodegradability, nontoxicity, and antimicrobial ability [270-272].
In this study, we used PLL with molecular weight between 500~2000 (average 
molecular weight is around 1250) and chitosan with molecular weight about 150,000 for 
emulsion coating. Because the unit number o f PLL and chitosan can be calculated 
respectively as 8.6 and 837.2 repeat units in their structure, it can be expected that PLL is a 
small molecule and chitosan is a huge molecules.
1.4.3 The behavior of coating materials 
As mentioned, we can expect improvement in the stability and performance of FOB 
emulsions if they are coated with something. However, it is fairly difficult to characterize 
the behavior of the coating materials on the emulsion surface because the measurement is 
complicated and technique is limited. The conformation or morphology of coating
materials would influence the function of the coating, and this would be affected by 
coating details, including surface concentration, temperature, and molecular weight of 
coating material. For example, similar complexity can be in many references wherein the 
function of surface-attached antigens is different when their conformation changes [273­
277]. The conformation of coating materials, especially of protein-based molecules, is 
critical to their function because some functional domain could be blocked due to the 
altered conformation. Some insight into the behavior of emulsion coating materials could 
be gleaned from thin films and Langmuir-Blodgett films [278-282], but being on a curved, 
submicron surface is significantly more complicated.
Since understanding of the conformation of coating materials is important to predict 
their performance/function in biology, pharmaceutics, and biomedical applications, in this 
study, we developed a model to measure/predict the conformation (expansion or 
compression) of coating materials using simple size and zeta potential measurements and 
basic calculation.
1.5 Techniques and theories in this work
1.5.1 Extrusion
Extrusion is the process of homogenization by membrane homogenizer to enable an 
emulsion to be formed with the desired particle size and uniform size distribution [283­
285]. The suspension of oil, aqueous solution, and surfactants is forced to pass through a 
membrane with the specific and uniform pore size by high pressure. In this study, 
emulsions were extruded by a 10 ml Thermobarrel LIPEX extruder (Northern Lipids, 
Burnaby, BC, Canada) and the membrane is a 100 nm pore size 25 mm diameter Millipore
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polycarbonate extrusion filter (Millipore). The suspension in the extruder connected to an 
air tank was under 100~500 psi at 22°C and against the membrane, 200 nm to form the 
emulsion. The extrusion process for the suspension was repeated 5 to 10 times until the 
emulsion reached the required size by verifying dynamic light scattering (DLS). It is worth 
remembering that membrane breaking could happen during extrusion if the pressure in 
extruder increases rapidly or the units of extruder are not installed properly.
1.5.2 Dynamic light scattering (DLS)
1.5.2.1 Size measurement
Dynamics light scattering (DLS), also known as photon correlation spectroscopy (PCS), 
is the device to measure Brownian motion and to relate this to the particle size [286-288]. 
Using a laser, DLS particles in a colloidal suspenion are illuminated and the fluctuations of 
the scattered light are analyzed to extract a particle size measurement. Particles suspended 
in a liquid randomly move in various directions due to Brownian motion. It can be assumed 
that larger particles move more slowly and smaller particles move more quickly. The 
relation of the particle size and their diffusional speed due to Brownian motion can be 
defined by Stokes-Einstein equation [178, 179], which has been illustrated in the section
1.3.3. The diffusion rate (D) depends on disperse liquid viscosity and the particle size. It 
can be shown as the following,
D = kb T / 6 n n r (1.5)
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where
kb is Boltzmann constant,
T is absolute temperature (Kelvin), 
n is the viscosity of dispersion medium, 
r is the particle size
Hence, DLS can measure the diffusion rate (D), and analyze the particle size(r) by 
setting two parameters: temperature (T) and disperse liquid viscosity (n). Because scattered 
light refracting from suspended particles varies according to the dispersant medium, 
particle composition, and particle concentration, the parameters of refractive index (RI) 
and absorbance (Abs.) of the dispersed medium and particles should be set in advance 
before size measurement. In this study, the Zetasizer Nano instrument ZEN3600 (Malvern 
Instruments) was used. The device enables us to measure particle size from 0.6 nm to 6 p.m 
and detects the scattered light from the front of the cuvette at an angle of 7° (173° 
backscatter mode). Disposable sizing cuvettes were used for size measurement, and they 
were cleaned by E-pure water and wiped carefully. In order to avoid the phenomenon of 
multiple scattering, it is suggested that the sample has to be very diluted. According to the 
Malvern’s manual of DLS, the sample concentration over which the sample can be 
measured is approximately 50 -  1000 ppm. Hence, 10 pl sample typically produced in this 
project was diluted by 1 ml E-pure water to form 1000 ppm approximately for size 
measurement. It also has a temperature extension option to 120 °C. The input parameters 
for DLS in this study could be shown in Table 1.1 [289-293].
The DLS instrument provides three types of size distribution curves, which are 
respectively, intensity distribution, volume distribution, and number distribution. The much 
light is scattered by the particles in different sizes. The volume distribution describes the
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Material Temperature (°C) Viscosity (cP) RI
Water 25 0.8872 1.330
Hexane 10 0.3442 1.375
Hexane 20 0.3131 1.375
Hexane 30 0.2892 1.375
total volume of particles in different sizes. The number distribution presents the total 
number of particles in different sizes. The three distributions are distinct but all relate to 
particle size. Considering that all particles are spherical and there are NA particles with size 
a, Nb particles with size b, NC particles with size c. . the relative contribution of intensity 
distribution is
%IA = ---- 6 W0NJ a6 (1.6)
A  N A a 6+ N B b 6+ N c C 6 +  --- v ’
The relative contribution of volume distribution is
0 / T/ __  __________lOON^a3__________  ^  _ s
0 !  _  N A a 3 + N B b 3 + N c C 3 + -  (  . )
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And the relative contribution of number distribution is
%Na = ---- -----------  (1.8)
!  n a +n b +n c + -  v  '
The sixth power of particle size used in the intensity distribution could over-emphasize 
the larger size objects in the sample, and similarly the size factor of number distribution 
could over-emphasize the smaller size group in the sample and ignore the larger size group. 
All the presentations of particle distribution are correct but they just have different physical 
meaning. Mie scattering gives a more complete explanation of the complicated scattering 
behavior. This theory is related to how the light is scattered from particles with various 
sizes while the optical properties like refractive index and absorbance of particles are 
known. Intensity distribution is not only just proportional to the size power of the particle 
size but corrected by a size-related Mie function M(a) [286, 294]. Generally, the 
presentation of intensity distribution is shown as,
_ ______ 1 0 0 M (a)______  (1 9)
0 A ~  N a M (a )+ N b M (b )+ N CM (c ) + •••  ^ '
Intensity distributions modified by Mie scattering are basically used in DLS 
measurements, so for mono-disperse specimens, it is usually more accurate to use the result 
of intensity distribution (it is also suggested by Malvern’s manual). Because the volume 
and number distribution of particle size are converted from intensity distribution later, the 
large group size of particles could be ignored during the distribution conversion. Therefore,
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intensity distribution was utilized to record as the particle size in this study. In the case of 
nongaussian particle distributions, one of the other presentations may be more useful.
1.5.2.2 Zeta potential measurement
Electrically charged colloidal particles that suspend in a dispersed solution attract ions 
in their surroundings. This results in the formation of electrical double layers around the 
particles, which are respectively, a Stem layer and a slipping layer (Figure 1.4). Ions that 
are strongly bound to the core charged particle form the Stern layer, and the potential 
between the stern layer and a point in bulk fluid away from the interface is called the Stem 
potential. The outer layer is referred to as the slipping plane where ions are less associated 
firmly. Zeta potential is the potential between the slipping plane (hydrodynamic plane of
Surface charge (negative)





Distance from particle surface
Figure 1.4 The notion of double layers and corresponding potentials of a charged particle.
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shear) versus a point in bulk fluid away from the interface. When the charged particle 
moves, the ions outside the slippage boundary would stay with the bulk dispersion medium 
while the others move with the particle [295, 296].
In electrokinetics, zeta potential could be meaured by means of electrophoresis, which 
is the movement of a charged particle relative to the liquid. The particle is suspended under 
the influence of an applied electric field. The behavior of electrophoretic mobility is 
determined by the Henry equation [297],
Ue = (1.10)
where
UE is the electrophoretic mobility,
8 is the dielectric constant of dispersion medium, 
z is zeta potential, 
f  (Ka) is Henry’s function, 
n is the viscosity of dispersion medium
In Henry’s function, f  (Ka), a is the particle radius and the reciprocal of k (1/k) is called 
Debye length (Xd) [298, 299], which is the thickness of double layers. The equation can be 
shown as the following:
(111)
where
£ is the dielectric constant of medium (£water = 78.5)
£0 is the vacuum permittivity
k  is the Boltzman’s constant
n io is the bulk concentration of ions with charge Zi
e is one electron charge
Henry’s function can be viewed as the ratio of particle radius to double layer thickness. 
Furthermore, Henry’s function of polar media like water can be simplified approximately 
to 1.5 by Smoluchowski’s formula [300, 301]. There are two assumptions: 1) the Debye 
length is much smaller than the surface radius o f curvature and 2) the zeta potential is small 
(ion distributions are only slightly disturbed). Zeta potential can then be acquired by 
measuring the electrophoretic mobility o f particles if  the viscosity o f dispersion medium 
and the dielectric constant o f dispersion medium are already known.
Zeta potential is also an important parameter that indicates the likely stability of 
colloidal system. If particles have high enough electrical charge on surface, the electrical 
repulsion will prevent them from flocculation. Generally, particles with zeta potential less 
than ± 30 mV would not be stable and would tend to aggregate [302, 303]. In this study, 
zeta potential was measured by Zetasizer Nano instrument ZEN3600 (Malvern 
Instruments). It is also used for size measurement. Based on Malvern’s manual, the sample 
for zeta potential has to be diluted prior measurement. Similarly, 10 pl of sample was 
diluted by 1 ml E-pure water to form 1000 ppm approximately for zeta potential 
measurements and a clear, disposable zeta cell was used. The parameters for DLS in this 
study are shown in Table 1.2.
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Material Temperature Viscosity RI Dielectric
(°C) (cP) constant
Water 25 0.8872 1.330 78.5
1.5.3 Acid dissociation constant and Henderson-Hasselbalch equation 
The chemistry reaction of acid dissociation represents the strength of an acid solution, 
and it can be quantified by the acid dissociation constant Ka (also known as acid-ionization 
constant or acidity constant) [304, 305]. The equilibrium of the reaction can be written as,
HA ^  H+ + A' (112)
So the equilibrium constant or acid dissociation constant can be written as,
K _  [!+] [!~] 
!  [!"] (113)
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Owing to the large orders of magnitude of Ka, a logarithmic representation of acid 
dissociation constant is more commonly used. Hence, logarithmic acid dissociation 
constant can be written as,
pKa = -lo g K a (1.14)
In chemistry or biology, the Henderson-Hasselbalch equation is usually used to 
estimate the pH of a buffer solution and to find the equilibrium pH of acid-base reaction 
[306-308]. The derivation of the Henderson-Hasselbalch equation can be shown as the 
following,
K„ =  ( I . I5)
logK„ =  log (1.16)
logKa = log [W+] + log j ! "  (1.17)
-pK„ = -p H  +  log (1.18)
pH = pK„ + log (1.19)
In practice, pKa can usually be found in previous references so the ratio of the 
concentration of dissociation acid (A') and undissociation acid (HA) could be known by 
measuring the pH of the acid solution. If the acid dissociation rate is 50%, which means the 
concentrations of dissociation acid (A') and undissociation acid (HA) are equal, the 
measured pH value would be the logarithmic acid dissociation constant (pKa). In this work, 
the concept was applied to verify the pKa of phosphate groups on lipids during the 
measurement of zeta potential versus pH.
1.5.4 Colorimetric determination of polylysine and chitosan 
Colorimetric determination is a method of analyzing the concentration of a chemical 
compound or chemical element in a solution by means of color reagent. The detected 
sample could be an organic or inorganic compound, and the determination could be 
involved in an enzymatic reaction or not. In this study, the concentration of polylysine and 
chitosan in solution were determined by colorimetric analysis. The different absorbance at 
a specific wavelength was verified by UV-Vis spectrometry after a colored reagent was 
added. The details are provided below.
1.5.4.1 UV-Vis spectrometry
Ultraviolet-visible (UV-Vis) spectrometry is an instrument to measure the absorption or 
reflectance spectra in the range of ultraviolet-visible wavelength by using the light in the 
visible and adjacent (near-UV and near-infrared) range. In the visible range, the absorption 
refers to the perceived color of the chemicals involved. In this range of the electromagnetic 
spectrum, molecules have electron transitions from the ground state to the excited state.
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This technique is complementary to fluorescence spectroscopy, which measures electron 
transitions from the excited state to the ground state. In both, electrons can be excited to 
higher antibonding molecular orbitals if molecules with n-electrons or nonbinding 
electrons (n-electrons) can absorb the energy in the form of ultraviolet or visible light [309­
311].
UV-Vis spectroscopy is extensively utilized for the qualitative and quantitative 
determination in analytical chemistry. The Beer-Lambert law quantitatively connects 
absorbance to concentration [312-314]. The basic equation of the Beer-Lambert law can be 
shown as,
A= s b c (1.20)
where
A is the absorbance of the sample 
s is the extinction coefficient or the molar absorptivity 
b is the pathlength through the sample 
c is the concentration of the sample
The absorbance of the sample is proportional to the concentration of the sample 
because the extinction coefficient (s) and the pathlength through the sample (b) are fixed. 
Generally, the extinction coefficient can be acquired from some reference and the 
pathlength through the sample can be known by measuring the cuvette length so the 
concentration of the sample can be found out if the absorbance is measured.
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In this work, colorimetric determination of PLL and chitosan were conducted using a 
UV Mini 1240 spectrophotometer (Shimadzu Scientific Instruments) and a 1 cm pathlength 
quartz cuvette. Another colorimetric experiment exploring phase transition temperature 
was completed using a more advanced Cary 100 UV-Vis spectrophotometer (Agilent 
technologies, CA), with temperature control kit and a 1 cm pathlength quartz cuvette.
1.5.4.2 Colorimetric determination of polylysine
Trypan blue (TB) is a dye with negative charges that is electrostatically attracted to 
positive PLL, and can be used for quantitative determination of PLL concentration. TB is 
attracted by PLL and precipitates the blue intensity o f unbound TB in the supernatant 
solution would decrease [315-317]. The scheme of this chemical reaction for PLL 
determination is shown in Figure 1.5. The basic procedure o f PLL colorimetric 
determination is to mix the PLL-containing sample with TB reagent and to place the 
mixture in a warm incubator (37 °C) for one hour. After that, the mixture is centrifuged to 
collect the precipitate and the supernatant solution is analyzed by UV-Vis spectrometry. 
Soluble TB (not precipitated) usually has an absorbance peak at 578 nm. If a standard 
curve of the absorbance of supernatant after TB is reacted with PLL and precipitated versus 
the concentration of PLL is created in advance, the concentration of PLL in solution can be 
easily measured by UV-Vis spectrometry. We similarly measure the emulsion bound 
concentration of PLL by measuring the amount o f free PLL remaining in the supernatant 









Figure 1.5 The precipitation mechanism of PLL and Trypan blue.
1.5.4.3 Colorimetric determination of chitosan
Cibacron Brilliant Red 3B-A, also known as Reactive Red 4, is the dye to utilize for 
chitosan quantitative determination because the dye with negative charges and the chitosan 
with positive charges on their amine groups tend to attract each other by electrostatic force. 
The scheme of chemical reaction of chitosan determination can be found in Figure 1.6. The 
basic procedure is to mix chitosan solution (dissolved by acetic acid so chitosan has 
positive charges in acid condition) with Cibacron Brilliant Red 3B-A in buffer solution. If 
the mixture solution is analyzed by UV-Vis spectrometry, it would cause bathochromic 
shifts (or called as red shift) so a sharp peak around 575 nm could be found [318-321]. 
Bathochromic shift is a change of spectral band position in absorption of a molecule to a 
longer wavelength, which means lower frequency. As the concentration of chitosan 
increases gradually, the phenomenon of bathochromic shift occurs obviously and the peak 
height at 575 nm is larger. If the standard curve of the absorbance of the bathochromic shift 





Chitosan Cibacron Brilliant Red 3B-A
Figure 1.6 The bathochromic shift mechanism of chitosan and Cibacron Brilliant Red 3B- 
A.
chitosan solution could be known when the absorbance is measured by UV-Vis 
spectrometry.
Fluorescence is the method of spectrochemical analysis where the molecules are 
excited from the ground state to the excited state in various vibrational states, by 
illuminating at a specific wavelength, and allowing them to relax by emitting radiation of a 
longer wavelength [322-324]. The lifetime of electron relaxation is fairly short, usually
ground state and the excited state minus any energy that is lost to vibration and thermal 
loss. In this work, fluorescence spectra were examined using a Cary Eclipse fluorescence 
spectrophotometer (Varian). The applied light is wavelength tuned to maximize absorption 
and therefore emission intensity. For stable measurements, the sample in the cuvette is 
covered with a lid on the top.
1.5.5 Fluorescent spectrophotometer
about 10"8 sec [325]. The emitted light’s wavelength depends on the band gap between the
1.5.6 Fluorescence quenching 
Any process that refers to the reduction of fluorescence intensity can be called 
fluorescence quenching. It can be the result of a variety of molecular interactions such as 
excited-state reactions, molecular rearrangements, energy transfer, ground-state complex 
formation, and collision [322]. Quenching often depends on pressure and temperature 
[326]. In this section, collisional or dynamic quenching between a fluorophore and 
quencher is described as it is used in the project.
In collisional quenching, the fluorophores have to encounter the diffused quenchers 
during the lifetime of their excited state. After contact, the fluorophores return to the 
ground state from their excited state, but no photon emission happens. In this process, the 
molecule of the quencher generally has no permanent change, which means there is no 
photochemical reaction. In contrast, the process of static quenching happens as the 
fluorophore and quencher contact and form a nonfluorescent complex [327, 328]. 
Molecular oxygen (O2), iodide ions (I-), and acrylamide (C3H5NO) are the best-known 
collisional quenchers [329-332]. The mechanism of quenching by oxygen, which has been 
debated, is likely that the fluorophore undergoes intersystem crossing to triplet state due to 
the paramagnetic oxygen [333, 334]. Another type of quenching mechanism is due to 
heavy atoms such as halogens: iodide or bromide. These halogen atoms cause intersystem 
crossing to an excited triplet state, promoted by spin-orbit coupling of singlet fluorophores 
and the halogens [335]. Due to slow emission from the triplet state, it would be highly 
quenched by other processes. A donation of an electron from fluorophore to the quencher 
happens because these halogen atoms are sensitive uniquely to quench by chlorinated or by
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electron scavengers like protons. In this work, iodide ions were applied to quench the 
fluorescent dye pyrene [336-338].
Collisional quenching of fluorescence (and phosphorescence) can be quantitatively 
described by the Stern-Volmer relationship [339]. The effect of quencher on steady-state 
fluorescence of a fluorophore can be simply described as the Stern-Volmer equation [340]:
where
I0 is the initial fluorescent intensity o f pyrene in absence of iodide ions
I is the fluorescent intensity o f pyrene quenched by iodide ions 
KS-V is the Stern-Volmer constant (M-1)
[Q] is the iodide ion concentration (M)
The dynamic Stern-Volmer constant is equal to the product of the bimolecular 
quencher rate constant (kq) times the excited state lifetime in absence of the quencher (t0), 
shown in the following equation:
!f = 1 + Ks_v [Q] (1.21)
K s_v — k q t 0 (1.21)
where
kq is the bimolecular quenching rate constant
t0 is the excited state lifetime in absence of the quencher
The bimolecular quencher rate constant, kq, is also equal to the product of the 
quenching efficiency, y, times the diffusion-limited bimolecular rate constant for collision, 
k, which is calculated theoretically by using the Smoluchowski equation [341-343]. It can 
be shown as the following equation:
k =  y k  =  O S#!!. (1.22)
!  '  1 0 0 0  v  '
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where
Y is the quenching efficiency
k  is the diffusion-limited bimolecular rate constant for collision 
D is the diffusion rate 
r is the molecular radius 
Na is Avogadro’s number
The diffusion rate (D) for different species can be predicted by the Stokes-Einstein 
equation. The viscosity (highly dependent on temperature and pressure [344]) and working 
temperature influences the fluorescent quenching. In this project, it needs to be 
remembered that a different results in the experimental measurement of pyrene quenching 
by iodide ions could occur due to the different viscosities of PLL and chitosan-coated 
emulsion suspension and need to be taken into consideration.
1.5.7 Fourier transform infrared spectroscopy (FTIR)
As a molecule absorbs the energy of ultraviolet or visible light, it undergoes electron 
transitions between different energy states but also vibrational and rotational energy 
transitions. The atoms in a molecule have quantized vibrational energy levels as they
vibrate around their equilibrium positions. The spacings o f energy levels are related to 
photon energies in the infrared region. Vibrations, generally, have several types like 
symmetric stretching, antisymmetric stretching, in-plane bending, and out-of-plane 
bending. Similarly, the atoms in the molecules also have quantized rotational energy levels 
whose spacings are related to photon energies in the microwave region [345-347]. The 
atoms in a molecule only stretch, bend, or rotate at specific frequencies corresponding to 
specific energy levels. In this way, infrared spectrum has been used extensively for 
identification of organic compounds [348-351]. It is more convenient to plot a frequency 
spectrum (the intensity versus various frequency) for the analysis o f organic or biochemical, 
but the interferogram signal cannot be interpreted directly. Fourier transformation can be 
applied to calculate and convert individual frequencies of interferograms into a spectrum. 
Fourier transform infrared spectrometer (FTIR) has been one of the important devices in 
organic chemistry analysis by infrared spectrum.
The infrared region of the electromagnetic spectrum covers the region from above the 
visible (7.8 x 10-7 m) to approximately 10-4 m, but organic chemists only use the midregion 
from 2.5 x 10-6 m to 2.5 x 10-5 m. In chemistry or biochemistry, frequencies are usually 
given in wavenumber, which is the reciprocal of the wavelength in centimeters. Hence, the 
unit of wavenumber can be expressed as cm-1 and the useful infrared region is from 4000 to 
400 cm-1. In the region from 4000 to 2500 cm-1, the absorptions are caused by N-H, C-H, 
and O-H single-bond stretching motions. N-H and O-H bonds absorb during the range of 
3300 to 3600 cm-1 and C-H bonds absorb during the range near 3000 cm-1. In the region of 
2500 to 2000 cm-1, the triple-bond stretching like nitriles or alkynes absorbs. In the region 
from 2000 to 1500 cm-1, all kinds of double bonds such as C=O, C=N and C=C absorb here.
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Carbonyl groups usually absorb in the range of 1680 to 1750 cm-1, and alkene groups 
absorb during the range of 1640 to 1680 cm-1. The region below 1500 cm-1 is the 
fingerprint region of infrared spectrum, which has various absorptions from the vibration 
of C-C, C-O, C-N, and C-X single bonds [352-354].
In this work, an FTIR (Excalibur 3100) with attenuated total reflectance (ATR) kit was 
used to verify the existence of PFOB in the emulsion. ATR is a technique used to enable 
the sample to be examined directly in solid or liquid state without sample preparation [355­
359]. In previous references, the carbon-fluorine bond stretching was identified to occur in 
the infrared region of 1360 to 1000 cm-1 [360, 361]. The wide region is because the 
stretching frequency is very sensitive to the location of substituents in the molecule. Mono- 
fluorinated chemical compounds exhibit a band between 1000 to 1110 cm-1 but 
multifluorinated compound can have two broad bands, which arise from symmetric and 
anitsymmetric vibrations [362].
Infrared spectroscopy is not only a powerful tool for the identification of organic 
chemicals (qualitative analysis) but is also a common technique for quantitative 
measurement [363-367]. The basic theory of FTIR quantitative measurement is based on 
the Beer-Lambert law, which has been illustrated in a previous section. Assuming the same 
pathlength through the sample and a constant, known extinction coefficient, the measured 
absorbance of a specific vibrational band is proportional to the concentration of measured 
chemical. To control the fixed pathlength through the sample, a demountable liquid cell 
(PIKE technology, WI) was used in this work. The schematic liquid cell is shown in Figure
1.7 (acquired from the website of PIKE technology). Liquid sample was injected into the 
center space of the spacer with a thickness of 0.015 mm (the pathlength through the
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Figure 1.7. The demountable liquid cell assembly layout
sample). According to the Beer-Lambert law, the concentration of the measured sample 
can be calculated by knowing the absorbance of the sample at the specific band. It is worth 
remebering that the absorbance could be slightly different due to the method of baseline 
determination. In this work, the baseline for FTIR quantitative measurement was taken as a 
fitted line straight line between the two lowest sides of the specific peak. The absorbance 
was defined as the height from the highest point of the peak to the sloping baseline. This 
approach has a slight error, but relative measurement between specimens should be 
accurate.
1.5.8 Cryogenic transmission electron microscopy (Cryo-TEM)
The basic principle of transmission electron microscopy (TEM) operation is similar to 
optical microscopy but uses electrons instead of light. The electron beam is applied such 
that it transmits through an ultrathin sample and interacts with the sample’s electrons as it
passes through. Due to de Broglie wavelength of electrons, electrons can provide high 
imagining resolution [368-370]. The wavelength of electrons of TEM depends on the 
energy of the accelerated electrons, which is related to the process known as thermionic 
emission from a filament. Theoretically, the resolution is limited by the wavelength of light 
or electron source according to Rayleigh criterion [371, 372]. The spatial resolution of 
TEM, basically, can be from nanometer to subangstrom so it can supply the morphology 
images of fine sample and plot the molecular structure from a diffraction pattern [373, 374]. 
However, the mean free path of electron gas interaction reduces and the electrical arc is 
generated if the electrons from filament go through the air directly [374, 375]. It is 
necessary to evacuate air in the TEM chamber to relative low pressure or vacuum, which 
means it is impossible to image the living or liquid samples without pretreatment via TEM 
[376-378].
A derivative technology, known as cryo-electron microcopy (cryo-EM) or electron 
cryomicroscopy, was proposed by Adrian et al. in 1984 [379]. In this method, the samples 
are studied at cryogenic temperature (generally liquid nitrogen temperature) without 
contrast agents to enhance electron density. This method of specimen preparation can 
preserve the sample in a state close to its original state. It can prevent damage of biological 
samples during preparation and the dehydration of particles in suspension. The sample 
should be rapidly plunged into liquid ethane with a high freezing rate greater than 
1,000,000 K/sec [380-382], and then is observed by electron microscopy. It is commonly 
used in the study of structural biology.
In this study, the emulsion could suffer from PFOB evaporation and structural rupture 
during TEM observation if emulsion is fixed directly on the TEM grid and air-dried. For all
! 45!
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samples, approximately 3.5 of solution was placed on a holey-carbon-coated copper 
grid, blotted, and plunge-frozen in liquid ethane using an FEI Vitrobot 
(Hillsboro). Samples were transferred to a Gatan 626 cryoholder (Pleasanton) cooled with 
liquid nitrogen. Cryo-TEM images were recorded at 200 kV in a FEI Tecnai F20 
transmission electron microscope (Hillsboro).
1.6 The work in the thesis
This thesis is mainly focused on the improvement of perfluorocarbon emulsion (PFOB 
emulsion is the primary material in this work) in terms of its structural stability and 
synthesis efficiency so that these materials can have greater potential in the area of 
artificial blood substitutes, MRI imaging, and drug delivery applications. Electrostatic 
coating of biomaterials on emulsion surfaces is fairly simple and can provide mechanical 
strength protection in blood vessels. The conformation prediction of coating biomaterials 
on the emulsion surface could be significant for future applications such as predicting the 
release rate of oxygen/ carbon dioxide and surface modification for specific targeting. In 
addition, a novel method of emulsion synthesis was developed by taking advantage of 
cosolvent to promote the emulsion uniformity without the generation of liposomes.
In the beginning of Chapter 2, PFOB was emulsified by various compositions of ionic 
and nonionic surfactants. The size and zeta potential of PFOB emulsion were measured to 
determine the optimal composition for PFOB emulsion. Later, the change of zeta potential 
of emulsion and coating materials at different pH was plotted, respectively, in Chapter 2. 
Emulsions coated by PLL and chitosan were then also described respectively using the 
change of size and zeta potential of coated PFOB emulsion at various concentrations of
coating materials and temperatures. By colorimetric determination of free PLL and 
chitosan, the concentration of coated materials on the emulsions could be calculated. A 
model for conformation prediction was established to compare PLL and chitosan coating 
on PFOB emulsion. Interestingly, the model used indicated these two molecules behaved 
oppositely. Finally, this result was verified experimentally by fluorescence quenching and 
the analysis o f thermodynamics.
In Chapter 3, a new synthesis process for producing PFOB emulsions using cosolvents 
was described and four types of emulsions were characterized by FTIR for PFOB retention. 
A phase transition temperature for the synthesis of PFOB emulsion was discovered and 
characterized via UV-Vis spectrophotometry. PFOB retention efficiency for the cosolvent 
synthesis of emulsion was obtained from quantitative measurement of the FTIR results. 
The emulsion uniformity without liposomes was confirmed using fluorescent dyes trapped 
in oil phase o f the emulsion and centrifugation to separate emulsion particles from any 
formed liposomes.




POLY-L-LYSINE AND CHITOSAN-COATED PERFLUOROCARBONS 
(PFCs) EMULSIONS: PROCESS AND CONFORMATION 
ANALYSIS OF COATING MATERIALS
2.1 Abstract
A technique for evaluating the conformation of poly-L-lysine (PLL) and chitosan (CS) 
on perfluorocarbons (PFCs) emulsions was developed. By means of the size and zeta 
potential of the coated emulsion, a change in the specific volume of PLL and CS molecules 
attached to the emulsion surface as their concentration increases was detected. 
Compression of PLL coatings and expansion of CS coatings on the emulsions was further 
verified by fluorescent quenching and supported by thermodynamic analysis. The approach 
developed is a convenient method for micro- and nanoparticulate coatings that cannot be 
easily probed by conventional optical or surface methods.
2.2 Introduction
Stability and performance control of surfactant-stabilized nanoemulsions in drug 
delivery, imaging, and other applications is enhanced when they are coated with other 
molecules that can provide chemical responsiveness [383-386], diffusional gating [387-
389], or target recognition function [390-393]. Little is known about the characteristics of 
these coatings at the molecular level. Typically, coatings are applied such that they 
maximally cover the surface, and it is assumed that the coating molecules retain their shape 
and physico-chemical characteristics as are found in solution. This assumption is probably 
incorrect as there are many examples of surface and concentration-dependent denaturation 
of molecules, such as polymer, proteins, and enzymes [394-397]. Naked and coating- 
reinforced nanoemulsions, liposomes, and other submicron-structures are highly 
investigated for biomedical applications, and the exact nature of the coating molecules is 
critical for understanding their biological and physiological behavior. For example, native 
and denatured conformations of a molecule may have widely varying ability to activate the 
immune system, bind complement, or interact with blood and tissues [398-402].
Molecular conformations of individual molecules in dilute solution can be probed 
indirectly in a variety of ways such as dynamic light scattering [403-405], neutron 
scattering [406-408], and Fourier transform infrared spectroscopy [409-412]. These 
indirect methods are difficult to apply to molecules tethered to nanoparticles. This is 
because both the molecule of interest and the nanoparticle have complex scattering 
signatures, single particle spectroscopic detection at the required resolution is difficult, and 
nanoparticle suspensions are usually at low concentration. Here, we present a simple 
method based on zeta potential measurements that permits following the assembly of a 
molecular coating on the surface of a nano- or microparticle, i.e., a submicron-sized 
spherical oil-in-water emulsion particle, and evaluating the changing conformation of the 





L-a-phosphatidylcholine (lecithin) from soybean and 1,2-dioleoyl-s«-glycero-3- 
phosphate (sodium salt) (DOPA) were purchased from Avanti®. Perfluorocarbon 1- 
bromoperfluorooctane (PFOB) was purchased from Oakwood Products, Inc. Sodium 
phosphate monobasic (NaH2PO4*H2O) and sodium phosphate dibasic, heptahydrate 
(Na2HPO4*7H2O) were acquired from Fisher Scientific and Mallinckrodt, respectively. 
Chitosan (Mr~150,000 g/mol) was acquired from Fluka and poly-L-lysine with average 
molecular weight from 500 g/mol to 2000 g/mol was acquired from Sigma-Aldrich®. 
Acetic acid (Mallinckrodt) and ethanol (Pharmco-AAPER) were used. 18.20 MQ-cm E- 
pure water was acquired from the machine Barnstead MicroPure ST (Thermo Scientific). 
MES buffer, Trypan Blue assay, Cibacron Brilliant Red 3B-A assay, and glycine were 
obtained from Sigma-Aldrich®. NaCl was obtained from VWR, and both HCl and NaOH 
were acquired from Mallinckrodt.
2.3.2 Synthesis procedure
Various compositions of DOPA-lecithin emulsions were synthesized according to the 
details listed in Table 2.1. DOPA mole percentage of total surfactants (DOPA and lecithin) 
is listed specially in the bottom of the table.
For a typical synthesis, Lecithin or Lecithin/DOPA solutions were first prepared in 
phosphate buffer (2ml of 0.2M NaH2PO4 *H2O and 298.68ml of 0.2M Na2HPO4*7H2O in 
859.25ml E-pure water, 18MQ cm resistivity). To this was added an amount of PFOB and 
the mixture stirred in a 20ml vial at 1200 rpm stirring for 30 min to disperse into a coarse
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Table 2.1 Various compositions of DOPA-lecithin emulsions (The MW of DOPA and 
lecithin are close. MWlecithm=775.0 g/mol, MWDOPA=772.5 g/mol)
Sample 1 2 3 4 5 6 7
Lecithin (10-3 moles) 2.33 2.31 2.28 2.23 2.21 1.16 0
DOPA (10-3 moles) 0 0.02 0.05 0.10 0.12 0.17 2.33
PFOB (ml) 1.60 1.60 1.60 1.60 1.60 1.60 1.60
Buffer (ml) 4.24 4.24 4.24 4.24 4.24 4.24 4.24
DOPA (%) of total surfactants 0.00 1 2 4 5 50 100
emulsion. The emulsions were then extruded through a 200 nm pore size polycarbonate 
membrane (Nuclepore Track-Etch membrane, Whatman) using a 10ml Thermobarrel 
LIPEX extruder (Northern Lipids, Burnaby, BC, Canada) for 5 times at 500 psi in room 
temperature. For comparison, mixtures of DOPA-only and lecithin-only emulsions were 
prepared at the following mole percentages spanning the range indicated for samples 2 
through 6 in Table 2.1.
For coating of the emulsions, 30 ^M CS and 4000 ^M PLL solutions were prepared, 
respectively. A solution of 30 ^M CS chitosan was made by adding 100 mg chitosan, 1ml 
acetic acid (Mallinckrodt), and 200pl ethanol (Pharmco-AAPER) into 18.8ml water. Solid 
chitosan can dissolve easier in water with the existence of acetic acid and ethanol. A 
solution of 4000 ^M PLL solution was made by adding 100mg poly-L-lysine into 19.9ml 
water. The final pH of CS and PLL solution were about 3.5 and 6.5 without any pH 
titration.
2.3.3 Coating
Five hundred pl of sample 3 emulsion (2D98L) in Table 2.1 titrated to pH 3.51, 3.57, 
3.62, 3.71, 6.95, 7.02, 7.08, 7.12, 7.19 were prediluted to 2.5 times of its original volume 
using E-pure water at room temperature. These nine samples were prepared for size and 
zeta potential measurement at several temperatures: 273, 278, 283, 288, 293, 298, and 
310K. For coating of emulsions, 500pl of sample 3 emulsion were prediluted to 2.5 times 
of it original volume using E-pure water and then mixed at room temperature (unless 
otherwise indicated) with varying amounts of 4000 pM PLL or 30 pM CS solution, as 
indicated in Table 2.2, and stirred at 150 rpm for 30 minutes. These nine samples of coated 
emulsion were titrated to pH 7.2. Another set of coatings with varying amounts of 4000 
pM PLL or 30 pM CS solution but no pH titration were applied at several temperatures: 
273, 278, 283, 288, 293, 298, and 310K. The temperature was also held constant all the 
time during size and zeta potential measurements. This examined temperature range (from 
0°C to 30°C) would be useful in future bio-applications and allows us to scrutinize coating­
relevant coating characteristics. The resulting set of mixtures is numbered from T1 to T7. 
Their composition is shown in Table 2.3. The reasoning behind use of sample 3 (2D98L) 
for coating studies will be explained in the results and discussion of emulsion synthesis.
2.4 Characterization
2.4.1 Dynamic light scattering (DLS)
Zetasizer Nano instrument ZEN3600 (Malvern Instruments, Malvern, Worcestershire, 
UK) and disposable sizing polystyrene cuvettes were used. The range for particle diameter 
measurement is from 0.6 nm to 6 pm. For diameter measurements, 10 pl sample was
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Table 2.2 Various compositions of coated emulsions.











Table 2.3. Various coating temperatures of coated emulsions.
Temp. (K) 273 278 283 288 293 298 310
P1T1 P1T2 P1T3 P1T4 P1T5 P1T6
P2T1 P2T2 P2T3 P2T4 P2T5 P2T6
PLL P3T1 P3T2 P3T3 P3T4 P3T5 P3T6 none
P4T1 P4T2 P4T3 P4T4 P4T5 P4T6
P5T1 P5T2 P5T3 P5T4 P5T5 P5T6
C1T1 C1T2 C1T3 C1T4 C1T5 C1T6 C1T7
C2T1 C2T2 C2T3 C2T4 C2T5 C2T6 C2T7
CS
C3T1 C3T2 C3T3 C3T4 C3T5 C3T6 C3T7
C4T1 C4T2 C4T3 C4T4 C4T5 C4T6 C4T7
diluted by 1 ml E-pure water. It would contain 4*10u emulsion particles in a 1 ml dilution 
sample, which is calculated from theoretical emulsion concentration later. The parameters 
of PFOB refract index and absorbance are 1.3 and 0.01, and of water viscosity and refract 
index are 0.8872 and 1.330. Both uncoated emulsion and coated emulsion were measured 
at 273, 278, 283, 288, 293, 298, and 310K, respectively, by the temperature control of DLS. 
Some samples were concentrated/viscous so extra care was taken to ensure samples were 
pipetted well and distributed uniformly.
2.4.2 Zeta Potential
Zetasizer Nano instrument ZEN3600 (Malvern Instruments, Malvern, Worcestershire, 
UK) was also used for zeta potential measurement. The disposable zeta potential cell made 
of polycarbonate with gold-plated beryllium copper electrodes was cleaned by E-pure 
water, and filled with 10 pl of the sample diluted by 1 ml E-pure water. The parameters 
used for zeta potential measurement were the same with size measurement. Only the water 
dielectric constant was additionally needed. Diluted PLL/CS solution was pH titrated 
before zeta potential measurement. Both emulsion and coated emulsion were measured at 
273, 278, 283, 288, 293, 298, and 310K by the temperature control of DLS.
2.4.3 pH
Titrations of pH of 5 ml PLL/CS solution, emulsion, and coated emulsion in a 20ml 
vial were performed by dropwise addition of 1M HCl or 1M NaOH. After pH titration, the 
liquid was stirred at 300 rpm for 1 minute. The added volume was 2-4 pl and much smaller
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than the bulk solution so the change of concentration could be ignored. The pH meter (Nist 
ACCMT AR60) and electrode used to measure pH were both from Fisher Scientific.
2.4.4 UV-Vis
UV Mini 1240 spectrophotometer (Shimadzu Scientific Instruments Columbia, MD) 
was used for colorimetric determination. All the samples measured were prepared in 1.5ml 
aliquots without dilution in 1 cm pathlength quartz cuvette. Samples were isolated from 
light during preparation using aluminum foil. The wavelength range of measurement was 
from 400 nm to 700 nm.
2.4.5 Modeling
MarvinSpace (ChemAxon, Hungary) was used to model the assumed structure of the 
emulsions used by this dissertation. Assumptions include: 1) the two hydrophobic tails of 
DOPA and lecithin stretch into PFOB core, 2) only the size of the lipid head group 
determines the thickness of the lipid layer, as well as the number of lipids needed to 
stabilize a PFOB droplet of given size, 3) there is only one lipid layer, and 4) the lipids are 
closely packed. The head group size of DOPA is approximately close to 5A (Figure 2.1(a)) 
and that of lecithin is about 8A (Figure 2.1(b)) so the thickness of one lipid layer is 
assumed to be 8A. Knowing the average emulsion particle size from DLS, the volume of 
PFOB in one particle can be calculated. Knowing the total amount of PFOB used and 
experimental sample (2D98L) described later is 68.4 nmol (The composition of sample is 
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Figure 2.1 Model of single lipid structure calculated by MarvinSpace. No lipid 
compression consideration, (a) The head group of DOPA is around 5A. (b) The head group 
of lecithin is around 8A. (c) The cartoon of emulsion shows that the hydrophobic tails of 
lipids would stretch into PFOB core. While calculating the diameter of PFOB core, the 
thickness of the lipid layer can be viewed as the size of the lipid head group, 
assuming no loss, the theoretical concentration of emulsion particles used in each
2.4.6 Colorimetric determination 
Spectrophotometric determination of PLL was performed using the Trypan blue (TB) 
assay [315, 316], The negatively charged dye interacts with positively charged PLL to 
form a precipitate via the reaction shown in Figure 2.2(a). (From our result, the pH of PLL 
solution and PLL-coated emulsion was around 6.5 to 7.2 so PLL had positive charges.) 
After centrifugation, the loss in intensity of blue color at 578 nm is used as a measure of 
the amount of free PLL in the suspension mixture and the amount attached to the 
nanoparticles is calculated assuming that no dye was adhered to the walls of 1.7ml 
microcentrifuge tubes. The system was calibrated using PLL solutions prepared in 0.1M 
MES with 0.15M NaCl at pH 6.5 that were serially diluted. The diluted concentrations of 
PLL solution were from 0 to 14.4 (iM. The assay solution consisting of 1.1 mM Trypan 
Blue in 0.1M MES buffer was mixed with the analyte solution, placed at 37°C for one hour, 
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Figure 2.2 The chemical reaction of colorimetric determination. (a) The mechanism of PLL 
and Trypan blue precipitation. (b) The bathochromic shift mechanism of chitosan and 
Cibacron Brilliant Red 3B-A.
solution was measured by UV/Vis spectrometry and correlated to the concentration of PLL 
solution.
The dye Cibacron Brilliant Red 3B-A (also called Reactive Red 4) was utilized for the 
quantitative determination of the chitosan. The reaction of negatively charged dye and 
positively charged amine groups of chitosan (in Figure 2.2(b)) causes a bathochromic (i.e., 
red) shift of the absorption peak to 575 nm from 536 nm [318-320]. To calibrate, an assay 
solution consisting of 5 ml 0.75 Cibacron Brilliant Red 3B-A solution was mixed with 
95ml buffer solution (81ml solution of 0.1M glycine and 0.1M
NaCl with 19ml 0.1M HCl at pH 3.5). The diluted concentrations of CS solution from 1.7 
to 2.7 ^M were used for standard curve, and the peak shift correlated with the CS.
Experimental samples of PLL- and CS-coated emulsions prepared with various 
concentrations of PLL and CL were centrifuged at 3000 rpm for 20 min at 273, 278, 283, 
288, 293, 298, and 310K, then the supernatant collected. (The centrifuging temperature is 
the same with the coating temperature.) The pellet material consisted mainly of coated 
emulsions because PFOB has the density close to 2 g/ml [413]. The supernatant solutions 
from PLL-coated emulsion samples were diluted to 50 times by ultrapure water and for 
CS-coated emulsion samples, C1, C2, C3, and C4, diluted to 4, 3, 2, and 1 times by 
ultrapure water to accommodate the narrow analysis range of the Cibacron Brilliant Red 
3B-A assay.
2.4.7 Thermodynamics analysis 
To understand the relation of coating concentration/temperature and coating material 
conformation, the analysis via thermodynamics was achieved. The following 
thermodynamics equation can be shown,
AG = —RTlnK = AH -  TAS (2.1)
where
R is the gas constant (8.314 kJ/mol'1K '1)
T is absolute temperature)
H is the enthalpy (kJ/mol)
S is the entropy (kJ/mol/K)
K is the equilibrium constant of coating reaction
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Using unbound PLL/CS unbound concentration from the colorimetric determination, an 
equilibrium constant for the coating reaction can be acquired and Gibbs free energy 
calculated. Various coated emulsions (shown in Table 2.3) were analyzed 
thermodynamically.
2.4.8 Fluorescent quenching
To evaluate the conformation of coating materials on the emulsion surface, the method 
of fluorescent quenching was applied. Pyrene (Xex=337 nm and Xem=394nm) is a 
fluorescent dye that can slightly dissolve in perfluorocarbon liquids [414] but only trace 
amounts in water [415]. Hence, we can assume the intensity from encapsulated pyrene is 
much higher than that from uncapsulated pyrene. Pyrene-labeled emulsions were prepared 
by mixing pyrene at a concentration of 4 mM with PFOB during sample 3-emulsion 
formation according to Table 2.1.
PLL- and CS-coated emulsions prepared with the emulsion 3 composition (the 
surfactant with 2% DOPA and 98% lecithin) and containing a total concentration of 1 mM 
pyrene were mixed with 5, 10, 20, and 50 mM KI solution to form mixtures that contained 
a final iodide concentration of 3.75, 7.5, 15, and 37.5 mM. Fluorescent measurements of
1.5 ml samples at 394 nm were taken before the addition of KI (I0) and at 30 min after 
mixing with KI (I). Data were also plotted according to the Stern-Volmer equation as I0/I 
versus [Q] to determine the efficiency of fluorescent quenching [360].
! 59!
I0/I = 1 + Ks-V [Q] = 1 + kqT0 [Q] (2.2)
where
Io is the initial fluorescence intensity of pyrene in absence of iodide ions
I is the fluorescent intensity of pyrene quenched by a known amount of iodide ions
KS-v is the Stern-Volmer constant (M-1)
kq is the bimolecular quenching rate constant (M-1S-1)
t0 is the excited state lifetime in absence of the quencher
[Q] is the iodide ion concentration (M)
The figures with the ratios of Io/I versus [Q] for PLL- and CS-coated emulsion were 
respectively plotted and the trend lines for the data points were fitted by linear regression.
2.5 Results and discussion
2.5.1 Emulsion synthesis 
Stable emulsion systems may be formed using charged or neutral lipids [416, 417]. 
Coating of emulsions by the controlled precipitation of secondary molecules has been 
demonstrated, but the mechanism involved varies [418-420]. In most cases, the emulsion 
particle acts as a sort of seed crystal onto which molecules at low concentration in the 
surrounding fluid attach. The driving force is the reduction in particle surface free energy. 
This process is accentuated if there is an accumulation of ions or coating precursors at the 
particle periphery. This results in a local concentration increase that then may exceed the 
solubility of the molecules and lead to rapid deposition onto the seed particle. Surface 
charge driven ion/molecule accumulation is particularly effective. Because lecithin is 
neutral, a phosphatidic acid lipid, DOPA, was added to the emulsion to increase the 
negative charge of the particles.
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The zeta potential of the resulting DOPA-lecithin emulsion particles was used to optimize 
the surface charge Figure 2.3(a). The zeta potential curve of emulsions prepared using a 
mixture of lecithin and DOPA was found to be nonlinear (Red squares Figure 2.3(a)). In 
contrast, simple admixtures of lecithin-only and DOPA-only emulsions (Blue squares 
Figure 2.3(a)) yield a linear change in zeta potential as a function of DOPA weight percent. 
The results suggest that less than 5% of DOPA is needed to make a significant increase in 
zeta potential in the mixed lipid emulsion.
The unusually rapid change in zeta potential with DOPA loading suggests complex 
phenomena are involved. Small amounts of DOPA appear to dramatically alter the 
interaction between emulsion particles via the electro-viscous effect [421, 422], as 
evidenced by a rapid increase in viscosity of the DOPA-lecithin emulsion as the amount of 
DOPA used increases. There is no evidence for emulsion-breaking and the primary 
particles retain a relatively constant diameter as measured with DLS (Figure 2.3(d)). It is 
likely that the zeta potential measurement is artificially increased to be more negative since
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Figure 2.3 Zeta potential and size of DOPA-lecithin emulsion. (a) The zeta potential of 
emulsions prepared with lecithin and DOPA lipids: mixed lipids (red squares), admixtures 
of single lipid emulsions (blue squares). Only a small amount of DOPA can make the 
surface charge of DOPA-lecithin emulsion more negative. (b) The concept of DOPA lipids 
(green) integrated into lecithin emulsion (blue). (c) The concept of mixture of DOPA 
emulsions (green) and lecithin emulsions (blue). (d) The size of various compositions of 
emulsions shows no obvious change.
as the viscosity increases, the electrophoretic mobility decreases and given the dielectric 
constant and Henry’s constant is unchanged, the measured zeta potential also must be 
larger, according to equation 1.10.
For the purpose of this project, 2 % DOPA and 98 % lecithin (2D98L) emulsion 
(Sample 3 in Table 2.1) was chosen to balance between high zeta potential and low 
viscosity.
2.5.2 Coating
The isoelectric points of PLL and CS were determined by measuring the zeta potential 
as a function of titration with acid and base (Figure 2.4). PLL is electrically neutral at pH 7 
and CS at pH 8. Due to gel formation of chitosan at the isoelectric point [423], a lower 
electrophoretic mobility results (according to equation 1.10), that effects measurement of 
the zeta potential at the high pH end of the chitosan curve in Figure 2.4(b). The zeta 
potential curve versus pH is not complete during the pH titration range. Hence, the shape 
of the titration curve of chitosan is different from PLL. The titration curve of 2D98L
a b
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Figure 2.4 Good region for coating. (a) The zeta potential versus pH curves of sample 3 
(2D98L emulsion) and PLL show opposite electric charge from pH 5.0 to pH 7.5. (b) The 
zeta potential versus pH curves of sample 3 (2D98L emulsion) and CS show opposite 
electric charge from pH 5.0 to pH 8.5.
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emulsion is more complex. The phosphate group of lecithin has one titratable proton, while 
DOPA has two (Figure 2.5). Hence, the first drop in the 2D98L emulsion curve can be 
viewed as the first titratable proton release from phosphate groups of both DOPA and 
lecithin. The midpoint of the first drop is at pH 2.86 close to the pKa1 2.12 of phosphoric 
acid. The midpoint of the second drop between a pH value 7.06 is close to the pKa2 7.21 of 
phosphoric acid and represents the second titratable proton of DOPA. The equilibrium 
reactions of phosphoric acid can be seen:
The emulsion and PLL have opposite electrical charge between pH 5.0 to pH 7.2 and CS 
between pH 5.0 to pH 8.5 with the greatest charge difference at around pH 7.2.
a o o
Lecithin
Figure 2.5 Chemical structures of DOPA and lecithin. (a) The phosphate group in the 
hydrophilic head of DOPA shows two available protons to release. (b) The phosphate 
group in the hydrophilic head of lecithin shows one available proton to release. Both are 
drawn by the software MarvinSketch.
Thus, this is the pH at which best coating should take place. Therefore, PLL and CS 
solutions at pH 6.5 and 3.5, respectively, were added to the 2D98L emulsion (Sample 3 
from Table 2.1) prepared at pH around 7.5 with an estimated concentration of 8.2* 1012 
particle/ml, containing roughly 46.2 micrograms of lipids. The pH of each sample after 
mixing was then adjusted to 7.2 and held for 5 min for equilibrium. Samples were then 
characterized with DLS and zeta potential (Figure 2.6). The average particle diameter 
increased linearly as a function of PLL added, largely due to aggregation at the highest 
PLL concentrations, but exhibited saturation behavior for CS without apparent aggregation 
(Figure 2.6(a) and 2.6(b)). Figure 2.6(c) and 2.6(d) show the zeta potential decreasing to 
below -10 mV at the highest PLL concentrations.
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Figure 2.6 Coated emulsions at pH 7.2. (a) PLL-coated emulsion diameter. (b) CS-coated 
emulsion diameter, (c) PLL-coated emulsion zeta potential, and (d) CS-coated emulsion 
zeta potential. At higher PLL concentrations, particles tend to aggregate because their zeta 
potential falls below -10 mV.
The results above, while suggestive, are not a direct proof that coating has been applied. 
Therefore, we developed a different approach in which we compared the zeta potential as a 
function of pH for uncoated (Figure 2.7) and coated 2D98L (Figure 2.8) emulsions. A 
significant jump in zeta potential is seen between pH 3 and pH 7 because proton 
concentration changes the surface charge of uncoated emulsion (Figure 2.4).
The size and zeta potential of 2D98L emulsion particles in Figure 2.7 did not change 
much as pH changed and temperature increased. For convenience, the average size and 
zeta potential of uncoated emulsions were used to plot in Figure 2.8. The temperature- 
dependent data were recorded in two pH groups avoiding the steep transition region (first 
group pHa is pH 3.51, 3.57, 3.62, and 3.71, and second group pHb is pH 6.95, 7.02, 7.08,
7.12, and 7.19). For PLL, the size and zeta potential measured at the same temperature in 
the second pH group were averaged for Figure 2.8(a) and 2.8(b). For the CS part, they were 
from the first pH group for Figure 2.8(c) and 2.8(d). Also, the pH difference of ionic 
strength for these samples can be ignored because the factor of phosphate buffer in 
emulsion would dominate mainly and all the samples have the same concentration of 
phosphate buffer.
For PLL-coated emulsions, the diameter of the resulting particle increases with the 
amount of coating material used with aggregation of particles at the highest coating 
concentration. Higher temperatures result in less aggregation. The corresponding zeta 
potential of the coated particles becomes less negative with the amount of coating material 
used and with temperature. For CS-coated emulsions, the size of the emulsion particles 
also increases with coating material used and with increasing temperature, while the zeta 
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Figure 2.7 Nine emulsion samples at various pH. (a) The size of 2D98L emulsion versus 
pH, and temperature. In the fixed temperature (except 310K), emulsion size stayed similar 
with varying pH. (b) The zeta potential of 2D98L emulsion versus pH, and temperature. In 
the same pH range (around pH 3.6 and 7.1), zeta potential did not change much at the fixed 
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Figure 2.8 Coated emulsions at various pH. (a) The diameter of PLL-coated emulsion. (b) 
The zeta potential of PLL-coated emulsion. (c) The diameter of CS-coated emulsion. (d) 
The zeta potential of CS-coated emulsion. No obvious trend for various coating 
concentration and temperature to size and zeta potential could be concluded at this point. 
Further data are necessary to find out the bound material concentration.
dramatically increasing at higher temperatures. This suggests that thetemperature- 
dependent properties of CS in this system are different from those of PLL.
In the analysis above, all data are plotted with respect to the amount of coating material 
used to make the sample. In order to be able to attribute the differences highlight in Figure
2.8 to the coating, it is necessary to correlate the results to the actual amount of coating 
material bound to the particles. The amount bound was calculated from the amount added 
and the direct colorimetric measurement of the amount unbound.
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2.5.3 Colorimetric determination 
The result of unbound and bound PLL and CS concentration was measured and 
calculated by colorimetric determination. In Figure 2.9, it shows the concentration of 
PLL/CS-bound coating materials versus coating concentration. The concentration of 
emulsion-bound PLL increases as the coating concentration increases but decreases for CS 
molecules. The amount of bound coating material as a function of applied coating amount
Figure 2.9 The bound PLL/CS concentrations are shown with various coating 
concentrations and different temperatures. From colorimetric determination results, the 
bound material concentration is temperature independent. The unexpected behavior of CS- 
bound concentration could be related to conformation changes.
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is temperature independent. Hence, we hypothesize that the unexpected behavior of bound 
CS concentration could be associated with concentration-dependent conformational 
changes of the molecules.
2.5.4 Modeling
Zeta potential measurements were used as an alternate means to determine the amount 
of coating. In a colloidal system, the electric potential as the function of the distance from 
particle is extremely complicated. It can be illustrated as the following equation [299] ,
where
y  is the potential at the distance l from the particle surface
8 is dielectric constant of medium
n io is the bulk concentration of ions with charge Zi
e is one electron charge
k  is the Boltzman’s constant
T is the absolute temperature
If the colloidal system has low charge density, the quantity (Z^ey/kT) would be less by 




0  =  e Kl (2.4)
where
y s is the Stern potential 
k is the reciprocal of Debye length
As the distance from the particle surface is equal to Debye length, the electric potential 
would be the zeta potential. In other words, the Stern potential is 2.7 times to the zeta 
potential, according to equation 2.4 (as l is equal to Debye length). Because the Stern plane 
is really close to the particle surface, we assume that the value of the Stern potential should 
be near to the surface potential. Moreover, surface charge density can be calculated from 
the surface potential by applying the following equation,
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a  = (2.5)
where
o is the surface charge density 
£ is the dielectric constant of medium (£water = 78.5)
£0 is the vacuum permittivity 
y 0 is the surface potential 
Xd is the Debye length (or k-1)
The surface charge can be obtained by using the area of particle surface so the surface 
charge change can be calculated after coating. Finally, by using the surface charge change 
and the charge of each coating material, the amount of coating materials on one emulsion 
can be derived. Before that, the Debye length is defined as the following equation,
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The following calculation of Debye length, Stern potential (viewed as surface potential), 
surface charge density, surface charge (Q), and surface charge change (AQ) can be 
arranged in Table 2.4.
The calculated number of bound molecules per single emulsion particle is estimated by 
dividing the change in surface charge by the charge of a single coating molecule. PLL 
with average molecule weight 1250 has 8.6 repeat units per molecule, and CS has 837.2 
repeat units per molecule. Hence, assuming each unit has one unit of electrical charge, then 
one PLL and one CS molecule would have a total charge of 1.37*10-18 C and 1.34*10-16 C, 
respectively. The results can be viewed in Figure 2.10. The number of PLL molecules per 
emulsion particle is much larger than that of CS. This can be readily explained by the 
difference of molecule weight of PLL and CS. As more PLL is added to the emulsions, the 
calculated number of PLL per particle increases independent of temperature. Because of its 
size, steric, and local charge hindrance, far fewer CS molecules need to interact with the 
emulsion surface to neutralize the charge. The reason for the difference of bound number is 
that the PLL we used is small molecules and CS is much bigger. A similar temperature 
dependence is seen for CS as in Figure 2.10(b) since the calculated results are derived from 
those measurements.
Since the surface charge density and number of surface charges occupied by a coating 
molecule are known, it is possible to back estimate the number emulsion particles involved. 
Based on the amount of material used and MarvinSpace estimates each identical emulsion 
sample used in this study should contain about 68.4nmol. Based on the following equations,
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Table 2.4 The profile of Debye length, stern potential, surface charge density, surface 
charge, and surface charge change of emulsion and PLL/CS-coated emulsion
Sample Xd (nm) Vs (mV) o (C/m2) 10-15 Q (C) 10'15 AQ (C)
E (pHb, T1) 0.746 -88.0 -0.818 -12.1 0
P1T1 0.746 -20.6 -0.019 -2.8 9.3
P2T1 0.746 -27.7 -0.026 -3.8 8.3
P3T1 0.746 -32.4 -0.030 -4.4 7.7
P4T1 0.746 -40.2 -0.037 -5.5 6.6
P5T1 0.746 -43.2 -0.040 -6.0 6.1
E (pHb, T2) 0.753 -84.8 -0.078 -10.3 0
P1T2 0.753 -20.8 -0.019 -2.5 7.8
P2T2 0.753 -20.8 -0.026 -3.4 6.9
P3T2 0.753 -34.0 -0.031 -4.1 6.2
P4T2 0.753 -42.4 -0.039 -5.2 5.1
P5T2 0.753 -61.7 -0.057 -7.5 2.8
E (pHb, T3) 0.760 -82.2 -0.075 -11.4 0
P1T3 0.760 -19.1 -0.017 -2.7 8.7
P2T3 0.760 -27.1 -0.025 -3.8 7.6
P3T3 0.760 -33.2 -0.030 -4.6 6.8
P4T3 0.760 -40.2 -0.037 -5.6 5.8
P5T3 0.760 -56.3 -0.051 -7.8 3.6
E (pHb, T4) 0.767 -83.7 -0.076 -11.4 0
P1T4 0.767 -19.6 -0.018 -2.7 8.7
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Table 2.4 Continued
Sample Xd (nm) Vs (mV) g (C/m2) lO'15 Q (C) lO‘l5 AQ (C)
P2T4 0.767 -26.8 -0.024 -3.7 -7.7
P3T4 0.767 -31.3 -0.028 -4.3 7.l
P4T4 0.767 -40.0 -0.036 -5.4 6.O
P5T4 0.767 -48.9 -0.044 -6.7 4.7
E (pHb, T5) 0.774 -80.5 -0.072 -1O.6 O
P1T5 0.774 -18.8 -0.017 -2.4 8.2
P2T5 0.774 -26.0 -0.023 -3.4 7.2
P3T5 0.774 -30.7 -0.028 -4.l 6.5
P4T5 0.774 -38.l -0.034 -5.O 5.6
P5T5 0.774 -50.3 -0.045 -6.6 4.O
E (pHb, T6) 0.780 -80.8 -0.072 -1O.5 O
P1T6 0.780 -16.9 -0.015 -2.2 8.3
P2T6 0.780 -22.2 -0.020 -2.9 7.6
P3T6 0.780 -26.6 -0.024 -3.5 7.O
P4T6 0.780 -29.6 -0.026 -3.9 6.6
P5T6 0.780 -44.3 -0.039 -5.8 4.7
E (pHa, Tl) 0.746 7.6 0.007 O.9 O
C lT l 0.746 107.4 o.ioo 13.4 12.5
C2T1 0.746 96.0 0.089 ll.9 ll.O
C3T1 0.746 93.2 0.086 ll.6 10.7
C4T1 0.746 66.l 0.061 8.2 7.3
73
Table 2.4 Continued
Sample Xd (nm) Vs (mV) o (C/m2) 10'15 Q (C) 10'15 AQ (C)
E (pHa, T2) 0.753 7.4 0.007 0.8 0
C1T2 0.753 116.3 0.107 13.5 12.7
C2T2 0.753 111.7 0.103 12.9 12.1
C3T2 0.753 97.9 0.090 11.3 10.5
C4T2 0.753 58.7 0.054 6.8 6.0
E (pHa, T3) 0.760 7.3 0.007 0.9 0
C1T3 0.760 126.1 0.115 15.2 14.3
C2T3 0.760 111.2 0.102 13.4 12.5
C3T3 0.760 81.6 0.075 9.8 8.9
C4T3 0.760 54.4 0.050 6.5 5.6
E (pHa, T4) 0.767 8.63 0.008 1.0 0
C1T4 0.767 108.7 0.099 13.1 12.1
C2T4 0.767 109.3 0.099 13.2 12.2
C3T4 0.767 76.9 0.070 9.3 8.3
C4T4 0.767 50.6 0.046 6.1 5.1
E (pHa, T5) 0.773 9.2 0.008 1.2 0
C1T5 0.773 88.9 0.080 11.4 10.2
C2T5 0.773 82.6 0.074 10.6 9.4
C3T5 0.773 80.7 0.073 10.4 9.2
C4T5 0.773 51.9 0.047 6.7 5.5
E (pHa, T6) 0.780 12.6 0.011 1.6 0
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Table 2.4 Continued
Sample Xd (nm) Vs (mV) o (C/m2) 10'15 Q (C) 10'15 AQ (C)
C1T6 0.780 60.1 0.054 7.5 5.9
C2T6 0.780 59.5 0.053 7.4 5.8
C3T6 0.780 54.9 0.049 6.8 5.2
C4T6 0.780 50.3 0.045 6.3 4.7
E (pHa, T7) 0.795 12.5 0.011 2.0 0
C1T7 0.795 50.0 0.044 8.1 6.1
C2T7 0.795 49.5 0.043 8.0 6.0
C3T7 0.795 47.6 0.042 7.7 5.7
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(2.8)
The total number of bound materials on total emulsion could be acquired by knowing 
the number of bound materials for one emulsion (Figure 2.10) and theoretical emulsion 
concentration (68.4nmol). In Figure 2.11, bound PLL and CS concentrations converted 
from total number of bound materials on total emulsions were plotted versus coating 
material concentration.
The apparent change in bound coating material concentration is quite large and is not 
easily explained by loss of emulsion particles. Rephasing of the emulsion system to form 
multilamelar lipid layers would have to result in breaking of the emulsion or expansion of 
the emulsion size, which is not true for the subset of data points in Figure 2.11. A likely 
explanation is expansion or compression of the coating molecules as they accumulate on 
the emulsion surface. A compression and expansion ratio (CER) can be defined as,
r .n D  _ Bound concentration by colorim etric determ ination— (2.9)
Bound concentration by theoretica l calculation
The numerator and the denominator are from Figure 2.9 and 2.11, respectively. If CER is 
larger than one, it means the coating materials on the emulsion surface compress. If CER is 

























Concentration (^M) Concentration (^M)
Figure 2.10 The number of bound PLL/CS. (a) The curve of the number of bound PLL per 
one emulsion versus coating concentration at various temperatures. (b) The curve of the 
number of bound CS per one emulsion versus coating concentration at various 
temperatures. There is no obvious trend of coated emulsions within various temperatures. 
The large molecule weight gap of PLL and CS makes the number of coating materials 





























Coating concentration (^M) Coating concentration (^M)
Figure 2. l l  The bound coating material concentration was obtained via theoretical 
calculation. (a) The bound PLL concentration versus PLL coating concentration at various 
temperatures. (b) The bound CS concentration versus CS coating concentration at various 
temperatures.
2.12, the CER values for PLL- and CS-coated emulsions are plotted against the amount of 
PLL and CS used in the coating procedure. In Figure 2.12(a), it shows PLL on coated 
emulsions would become more compressed and increases packing density as PLL 
concentration goes higher. However, CS on coated emulsions would become more 
expanded when increasing CS concentration. In Figure 2.12(b), CS emulsions coated at 
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Figure 2.12 CER values. (a) The curve of CER versus PLL-coating concentration at 
various temperatures. (b) The curve of CER versus CS-coating concentration at various 
temperatures. With the increase of PLL concentration, PLL molecules on the emulsion 
surface become more compressed. Reversely, CS molecules on the emulsion surface 
become more expanded as CS concentration increases.
coated at lower temperature. This is why CS molecules on emulsion coated at higher 
temperature can be more compressed than those coated at lower temperature.
2.5.5 Thermodynamic analysis of coating process 
Emulsion with varying coating concentration and temperature could be complex due to 
the conformation change of coating materials. One way to evaluate the tendency of 
favorable or unfavorable coating is via thermodynamic analysis. By means of colorimetric 
determination of PLL and CS, the binding constant (Kb) can be known (equation 2.10).
Kh = [Bound, coating m aterials]






The concentration of bound coating materials and unbound coating materials was 
determined colorimetrically. In the initial emulsion concentration (68.4nmol), the
concentration of bound coating materials and the calculated number of coating materials on 
one emulsion could decide the concentration of unbound emulsions. In Figure 2.13, the Kb 
is shown at various coating concentration and temperature. Binding constants of PLL keep 
steady until the last high PLL coating concentration. The increment Kb at highest 
concentration means more PLL was attached to the nearly neutral coated emulsion surface. 
For CS, the lower coating concentration is, the higher binding constants they show. 
However, there is no specific trend of binding constant change at various temperatures.
Based on equation 2.1, the Gibbs surface free energy during the coating reaction at 
various temperatures is shown in Figure 2.14(a) and 2.14(b). The change of Enthalpy (AH, 
kJ/mol) and entropy (AS, kJ/mol/K) can be deduced by linear regression. The free energy 
represents the electrostatic binding of coating material to the emulsion surface during the 
coating. The negative slopes of the lines mean AS is a positive quantity consistent with a 
spontaneous process (AS>0) so increasing the coating tends to move the system to a more 
stable energy state. In Figure 2.14(a), the samples with PLL coating concentrations of 200,
78
Figure 2.13 Binding constants. (a) Binding constant of PLL at various coating 
concentration and temperature. The binding constant of PLL increased as higher PLL 
coating concentration was applied. (b) Binding constant of CS at various coating 
concentration and temperature. The binding constant of CS decreased as higher CS coating 
concentration was applied. It is still difficult to realize the physical relation between 
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Figure 2.14 Free energy. (a) Emulsion coated by PLL concentration 1000 pM had lowest 
Gibbs surface free energy because the conformation of PLL became more compressive (b) 
The Gibbs surface free energy of CS-coated emulsion was lower as coating concentration 
was lower due to the compressive CS conformation.
400, 600, and 800pM have the same slope (AS) and intercept (AH), but the samples with 
PLL coating have a concentration of 1000 pM (higher concentration is different, with AG 
more negative). This result suggests that the emulsion surface is highly attractive to PLL, 
which reduces its surface energy initially, until a steady state surface energy is reached. 
Presumably, if we were to add additional PLL, the coating process would continue. The 
phenomenon in protein in which specific volume contracts during protein concentration 
increases is found in previous reference [424, 425]. The idea of macromolecular crowding 
is also similar, in which high concentration of protein alters its own conformation [426, 
427].
In contrast, AG is more negative at lower CS coating concentration, suggesting that 
coating is more favored as more CS is bound to the emulsion. This can only be explained if 
the conformation of CS on the surface is changing in such a way as to increase the affinity 
for more binding. That some sugar expands or swells during the increment of its 
concentration is also found due to extra water uptake [428].
2.5.6 Fluorescent quenching 
To prove that the packing density of coating molecules on the emulsions is a function 
of coating concentration, fluorescence quenching was used. Pyrene-doped PFOB 
emulsions were coated with PLL and CS and exposed to 5, lO, 2O, and 5OmM KI to form 
mixtures with final concentrations of 3.75, 7.5, 15, and 37.5mM. When the emulsion 
coating is in an expanded state, the iodide ions should be able to pass through the coating 
and interact with the pyrene at the emulsion/coating interface (Figure 2.15). The solubility 
of pyrene in water is relative slight (about l~3^M) due to its hydrophobic aromatic 
structure [429, 43O]. Hence, the fluorescent from pyrene in water is neglectable, which is 
compared to the pyrene doping concentration in PFOB (4mM). Although it would be 
difficult for iodide ions to pass through the PFOB core, they could quench pyrene 
accumulated near the surface of the PFOB core at least.
The fluorescent quenching of uncoated pyrene-doped emulsion in water as the control 
group is shown in Figure 2.16 to see if air affects the fluorescent quenching much because 
oxygen is one kind of quencher. It can be found that oxygen would cause fluorescent 
quenching slightly. Hence, it can be considered that all the fluorescent quenching is caused 
only by iodide ions in the following experiments. Because iodide is negatively charged, its 
efficiency for quenching pyrene depends on accessibility to pyrene. The emulsion surface 
charge, the density of the coating layer, and the overall viscosity of the suspension will 
affect the diffusion rate of ions. If the rate of diffusion is lower than the relaxation time of 
the dye, then there will be no quenching during the lifetime of the dye, except when a large 







Figure 2.15 The proposed scheme for the reaction of iodide ions and pyrene is shown. The 
iodide ions can pass through the diffuse coating layers and quench the pyrene at the PFOB 
core oeripher (green lines indicate the routes).
2D98LP emulsion in water
Time (min)
Figure 2.16 The fluorescent quenching of uncoated pyrene-doped emulsion by oxygen in 
the air is shown. All the measurement was done in the glass cuvette with the lid so the 
factor about oxygen quenching is limited.
Figure 2.17(a) shows that the ratio of I0/I for pyrene in the PLL-coated emulsions increases 
linearly with iodide quencher concentration, but that there is more quenching for lower 
coating concentrations. This behavior is normally what would be expected for increasing 
coating density. In Figure 2.17(b), it is shown that for CS-coated emulsion, there is also 
more quenching when higher quencher concentration is used, but there is more quenching 
when a larger amount of CS is attached to the particles. This represents an unusual 
behavior, but does make sense in the context of the results of the previous section where it 
was inferred that CS molecules expand on the emulsion surface as their concentration 
increases. Considering the quencher concentration, as the KI concentration increases, the 
viscosity of the suspension increased so that the diffusion of iodide ions is slowed so there 
is less dynamic quenching possible. A Stern-Volmer constant (KS-V) (Table 2.5) can be 
acquired from the slopes of the trend lines (linear regression) in Figure 2.17. The trend 
lines of the ratio of I0/I versus [Q] for the CS-coated emulsion only are determined by the 
KI concentrations: 3.75, 7.5, and 15mM. The bimolecular quenching rate constant (kq) can 
also be deduced using the pyrene fluorescent excited state lifetime (t0) in air-equilibrated 
water, 126ns [431]. The reason may be that the CS-coated emulsion surface has positive 
charges to attract the negatively charged iodide ions, but the PLL-coated emulsion surface 
has negative charges, shown in Figure 2.8(b) and 2.8(d).
Based on the result of defined CER ratio calculation shown in Figure 2.12 (as CER is 
larger than 1, the conformation of the coating material tends to be more compressed; as 
CER is smaller than 1, the conformation of the coating material tends to be more expanded) 
and the experiment about fluorescent quenching results, we can propose a concept for PLL 
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Figure 2.17 Fluorescent quenching results. (a) The ratio of the initial fluorescent intensity 
to the final fluorescent intensity versus the quencher concentration for PLL-coated 
emulsion is shown. As I0/I is higher, it means iodide ions can pass easier through the more 
expanded coating layer at lower PLL concentration. (b) The ratio of the initial fluorescent 
intensity to the final fluorescent intensity versus the quencher concentration for CS-coated 
emulsion is shown. As I0/I is higher, it suggests iodide ions can pass easier through the 
more expanded coating layer coated by higher CS concentration. When considered as a 
function of quencher concentration, regardless of the coating levels, quenching is reduced 
because the higher ion concentration causes a dramatic increase in suspension viscosity and 
reduction of dynamic (collisional) quenching.
Table 2.5 Stern-Volmer constants (KS-V) and bimolecular quenching rate constant (kq) of 
coated emulsion in various concentrations of KI solution
Conc. (^M) Trend line slope R2 Ks-v (M-1) 10-9 kq(M-1S-1)
1000 0.00556 0.8788 5.6 0.044
800 0.00523 0.7780 5.2 0.042
600 0.00421 0.9995 4.2 0.033
400 0.00411 0.9745 4.1 0.033
200 0.00437 0.9369 4.4 0.035
10.4 0.08018 0.9918 80.2 0.636
8.3 0.07078 0.9806 70.8 0.562
6.3 0.05123 0.9899 51.2 0.407
4.2 0.04614 0.9870 46.1 0.366
ba
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Figure 2.18 The conformations of the coating materials, (a) PLL-coated emulsion has more 
expanded surface during low coating concentration, (b) PLL-coated emulsion has more 
compressed surface during high coating concentration, (c) CS-coated emulsion has more 
compressed surface during low coating concentration, (d) CS-coated emulsion has more 
expanded surface during high coating concentration.
molecules on the emulsion surface pack loosely when the coating concentration is lower, as 
shown in Figure 2.18(a). Once PLL coating concentration increases, PLL molecules pack 
more tightly via electrostatic attraction on the emulsion surface in Figure 2.18(b). In 
contrast, CS molecules on the emulsion surface pack tightly in Figure 2.18(c) at lower CS 
coating concentration but rephase to looser packing at the higher concentration (Figure 
2.18(d)). Hence, it can be concluded that PLL molecules on the emulsion surface become
more compressed and CS molecules on the emulsion surface become more expanded while 
the coating concentration increases. The reversed result of conformation change could be 
possibly related to the large difference between the molecular weight of PLL and CS.
2.6 Conclusions
This work shows an analysis of an emulsion coating process that in addition to 
providing information about the thermodynamics of coating reveal something fundamental 
about the characteristics of the coating molecules as the particles are formed. The ionic 
surfactant DOPA was used to create a negative surface charge on an emulsion make from 
98% nonionic surfactant lecithin. One formulation with maximum surface charge and 
minimum modification (2% DOPA and 98% lecithin PFOB emulsion prepared at pH 7) is 
for measurement of binding equilibrium as a function of temperature and coating formation, 
and for zeta potential measurements as a function of coating formation. PLL and CS 
exhibited different coating characteristics explained by concentration and pH-dependent 
conformational differences. By using the measurements to back calculate the bound 
coating material concentration, it is possible to discern a change in the specific volume of 
the coating molecules that follows the expected trend for protein and sugar molecules in 
concentrated solution. The trend is rationalized due to the high local concentration of these 
molecules as they accumulate and attach to the emulsion surface. PLL molecules tend to 
compress on the coated emulsions as the coating concentration increases. Conversely, CS 
molecules tend to expand as the concentration increases. The effect of compression versus 
expansion was further validated by means of fluorescent quenching. The ratio of initial 
fluorescent intensity to final intensity is higher for lower PLL coating concentration and
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higher CS coating concentration, supporting the hypothesis that at these two extreme 
concentration ranges, both conformations of the coating materials are expanded and create 
a more porous coating that can be easily permeated by small charged ions. Thermodynamic 
calculations also support this picture.
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CHAPTER 3
METHOD TO IMPROVE THE ENCAPSULATION OF 
PERFLUOROCARBONS (PFCs) IN OIL-IN-WATER 
(O/W) EMULSIONS USING COSOLVENT
As pointed out elsewhere, the purpose of this project is to produce a reinforced, 
perfluorocarbon-based blood substitute via electrostatic layer-by-layer coating of biological 
polymers with high production yield. In Chapter 2, the relation of polymer structure to 
emulsion phase stability and dynamic changes of the polymer conformation on emulsion 
surface were introduced. The next challenge is to manufacture emulsions at high yield. Here, 
a novel method of emulsion synthesis would be proposed.
3.1 Abstract
Perfluorocarbon oil-in-water (O/W) emulsions are challenging to produce in high yield 
due to the large hydrophobicity of perfluorocarbons and the high affinity of emulsifier for 
water and production of liposomes. Therefore, traditional emulsification processes are 
inefficient, and the result is a mixture of emulsion, liposomes, and excess oil/surfactants. 
To improve yields, various cosolvents were tested along with a low temperature vacuum 
drying method. FT-IR was used to relatively quantify the amount of perfluorocarbon
88
remaining in the mixture after this process and the result compared with standard 
mixing/extrusion methods. Hexane as the cosolvent had the best ability to product high- 
yield perfluorocarbon emulsions. Fluorescence methods were used to show that this 
method also reduces the formation of liposomes. Emulsions made by the direct-emulsified 
method and our new method (cosolvent method) had different sediment behaviors 
consistent with the higher density of the more pure emulsion preparation. The novel 
method exactly provides the possibility of high yield of emulsion synthesis.
3.2 Introduction
Oil-in-water (O/W) emulsions have been widely used in cosmetics, health care, food 
industry, firefighting, and pharmaceutical applications [432-441]. Using a ternary phase 
diagram or hydrophilic-lipophilic balance (HLB) rule, the ratio of oil, water, and surfactant 
can be easily selected to optimize the formation of O/W emulsions [442, 443]. However, 
these approaches obscure the reality that the demarcation of phases is blurry and that 
mixtures of phases exist throughout. For many applications, it is critical to have highly 
efficient production of the desired phase and minimize side products.
Perfluorocarbons (PFCs) O/W emulsions are an example of a system that is difficult to 
produce in concentrated, purified form because the available emulsifiers have difficulty 
mixing with the highly hydrophobic oil. Most PFC-based O/W emulsions are mixed phases. 
Mechanical methods such as extrusion are often insufficient to create a pure O/W phase. 
Here, we explore a cosolvent method to increases the yield of O/W emulsion and compare 
it to conventional methods such as extrusion.
3.3 Experimental method
3.3.1 Materials
Surfactant, 95% L-a-phosphatidylcholine (lecithin) from soybean was acquired from 
Avanti®. perfluorocarbon 1-bromoperfluorooctane (PFOB) (partial pressure PPFOB: 
6.5mmHg at 20oC) was purchased from Oakwood Products, Inc. Four organic liquids: 
>99.9% methanol (partial pressure Pmethanol: 140.1mmHg) from Sigma-Aldrich, >99.5% 
ethanol (partial pressure Pethanol: 58.7mmHg) from Sigma-Aldrich, >99.8% chloroform 
(parital pressure Pchloroform: 198.1mmHg) from Mallinckrodt chemicals, and >99.0% hexane 
(partial pressure Phexane: 153.5mmHg) from Sigma-Aldrich were obtained [444]. Pure water 
(18.2 MQ-cm) was produced using a Barnstead E-Pure (Barnstead/Thermolyne) ultrapure 
water system.
3.3.2 Cosolvent selection 
For emulsions made using the cosolvent method, 10 ml of cosolvents were respectively 
mixed with 1 ml PFOB, and 1 g lecithin added while stirring magnetically at 1000 rpm for 
30 min at room temperature (20°C). The molar ratio of lecithin to PFOB is about 1 to 4. 
The mixtures were allowed to rest in a closed container overnight then placed into a 
vacuum chamber at 4°C for 10 hours to evaporate the cosolvent. After this, 10ml of E-pure 
water was added to the mixture and stirred with 300 rpm at room temperature for 10 min. 
FTIR was applied to verify if PFOB retained.
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3.3.3 Emulsion with cosolvent method 
For emulsions made using the cosolvent method, 10 ml of hexane was mixed with 1 ml 
PFOB, and 1 g lecithin added while stirring magnetically at 1000 rpm for 30 min at 4 °C. 
The mixtures were placed into a vacuum chamber at 4 °C for 10 hours to evaporate the 
cosolvent. After this, 10 ml of E-pure water was added to the mixture and stirred at 300 
rpm at room temperature for 10 min. The emulsion made by the cosolvent method is 
denoted as HPL emulsion. Where indicated, the emulsions were then extruded through a 
600 nm pore size polycarbonate membrane (Nuclepore Track-Etch membrane) using a 10 
ml Thermobarrel LIPEX extruder (Northern Lipids) 5 times at 500 psi in room temperature.
3.3.4 Emulsion with direct-emulsified method 
For emulsions produced via extrusion method, 1ml PFOB, 1 g lecithin added, and 10ml 
water were mixed at the same time and stirred in 20 ml vial at 1200 rpm stirring for 30 min. 
The emulsions were then extruded through a 600 nm pore size polycarbonate membrane 
(Nuclepore Track-Etch membrane) using a 10 ml Thermobarrel LIPEX extruder (Northern 
Lipids) 5 times at 500 psi in room temperature. For the convenience, the emulsion made by 
direct-emulsified method is denoted as DE emulsion.
3.4 Characterization
3.4.1 Fourier transform infrared spectroscopy (FTIR)
An Excalibur 3100, Varian Inc. FTIR recording measured at 4 cm-1 resolution and 
averaging 64 scans were used to measure the relative PFOB content of the emulsions. 
Samples were placed in attenuated total reflectance (ATR) kit for measurement.
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The region for C-F stretch is found between 1000 cm-1 and 1360 cm-1 and is diagnostic 
for the presence of PFOB in the samples. For molecules with one fluorine, one strong 
signal between 1000-1110 cm-1 is seen, and for molecules with multiple fluorine atoms, 
this peak splits into one symmetric peak and another asymmetric peak [346].
Spectral analysis was used to quantify the relative amount of PFOB remaining in the 
samples produced after the vacuum drying step. To do this, hexane was added to resuspend 
the emulsion instead of water. A demountable liquid cell (PIKE technology, WI) was used 
in this work. Liquid sample was injected into the center space of the spacer with a 
thickness of 0.015 mm (the pathlength through the sample). According to the Beer- 
Lambert Law, A= sbc, where A is the absorbance, s is the absorptivity co-efficient (L mol-1 
cm-1), b is the pathlength of light in the sample (cm), and c is the concentration of the 
sample (mol/L), the absorbance of the specific peaks on FT-IR spectra should be 
proportional to the functional group concentration in the sample when measured under the 
same conditions. The specific peak of carbon-fluorine bond at 1242 cm-1 was applied, and 
the peak height was acquired by drawing a baseline between the left and right lowest points 
of the specific peak. Hexane and PFOB mixtures were used to establish a calibration curve 
and the PFOB content in the experimental samples determined from this curve.
3.4.2 Phase transition temperature (PTT)
The optical clarity of the PFOB/hexane/lecithin mixture before vacuum drying was 
measured using the total amount of scattered light at 525 nm from 0 °C to 30 °C using a 
Cary 100 UV-Vis spectrophotometer with temperature control (Agilent). The particle sizes 
of lecithin in hexane and PFOB at 10 °C, 20 °C, and 30 °C were measured by dynamic
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light scattering (DLS) using a Zetasizer Nano ZEN3600 from Malvern Instruments. Table
3.1 shows the required parameters for size measurement of the study [289-293].
Two emulsions made using hexane as the selected cosolvent were prepared for the 
remaining studies) at 0 °C (opaque) and 30 °C (transparent), respectively. FTIR was used 
to measure the amount of PFOB retained.
3.4.3 Fluorescence
To compare the ratio of liposomes generated in PFOB emulsion, emulsion was 
synthesized by direct-emulsified and cosolvent methods. Two fluorescent dyes, 
fluorescein (0.6 mM) and pyrene (4.0 mM), were added into prepared PFOB emulsions. 
Fluorescein with carboxyl and hydroxyl groups in its structure has slight solubility in water
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Material Temperature (°C) Viscosity (cP) RI
Water 25 0.8872 1.330
Hexane 10 0.3442 1.375
Hexane 20 0.3131 1.375
Hexane 30 0.2892 1.375
[445] but not in PFOB. Nonpolar pyrene with flat aromatic can slightly dissolve in water 
(1~3 pM) [429, 430] but has much higher solubility in nearly nonpolar PFOB. Hence, 
fluorescence from fluorescein in the sample can be viewed as the existence of liposomes. 
The presence of a large pyrene emission should indicate a large quantity of PFOB emulsion. 
First, 0.6 mM solutions of fluorescein in 10 ml water and 10 ml PFOB were made, 
respectively. Next, 4.0 mM solutions of pyrene in 10 ml water and 10 ml PFOB were made, 
respectively. The undissolved pyrene would be removed during extrusion (600 nm), and 
undissolved fluorescein was removed before resuspending vacuum-dried solid by 0.2 pm 
syringe filter (Whatman). The fluorescence of four samples doped with fluorescein or 
pyrene was analyzed. The detailed information about the four samples is shown in Table 
3.2.
For DE emulsion, two samples were produced. One sample contained mixed 1.0 g 
lecithin, 1 ml PFOB, and 10ml water with 0.6 mM fluorescein and was extruded through a 
600nm membrane. Another contained 1.0 g lecithin, 1 ml PFOB with 4.0 mM pyrene, and 
10 ml water. Each were mixed and extruded through a 600 nm pore size membrane. Both 
samples were dialyzed against E-Pure water after extrusion using membrane tubing with 
molecular weight cut-off (MWCO) 3500 g/mol, from VWR Scientific. For HPL emulsion, 
two PFOB emulsion samples were also synthesized. One sample was a mixture of 1.0 g 
lecithin, 1 ml PFOB with 4.0 mM pyrene, and 10 ml hexane. Another one was a mixture of 
1.0 g lecithin, 1 ml PFOB, and 10ml hexane. Each was vacuum-dried at at 4 °C for 10 
hours. For resuspension, the sample with pyrene was added 10 ml water and the sample 
without pyrene was added 10 ml 0.6 mM fluorescein solution. Both samples were later 
extruded through a 600 nm pore-size membrane and dialyzed against E-Pure water. For
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S1 DE fluorescein 0.6 480 518
S2 DE pyrene 4.0 337 394
S3 HPL fluorescein 0.6 480 518
S4 HPL pyrene 4.0 337 394
each of the four samples, fluorescence emission was recorded for the PFOB emulsion 
before extrusion, after extrusion/before dialysis and after dialysis.
In this work, fluorescence spectra were measured using a Cary Eclipse fluorescence 
spectrophotometer (Varian). Fluorescence measurements were performed using a 
photomultiplier tube detector set at a voltage of 400 volts. All samples were measured in a
1 cm pathlength quartz cuvette covered by a lid at room temperature. For the samples with 
fluorescein, the excitation wavelength was set at 480 nm and the expected emission peak 
would be at wavelength 518 nm. For the samples with pyrene, the excitation wavelength 
was set at 337 nm and the expected emission peak would be at wavelength 394 nm.
3.4.4 Centrifugation
To prove the difference of PFOB emulsion amount by cosolvent and direct-emulsified 
methods, centrifugation by density was applied (rPFOB=1.93 g/ml). Centrifugation of the 
prepared samples (HPL emulsion with 600 nm extrusion and DE emulsion) was done at
2000 rpm for 10 min using a 5417C Eppendorf microcentrifuge. Emulsions with 
significant PFOB content should be easier to pellet by centrifugation, leaving behind empty 
liposomes and other low-density debris. HPL emulsions prepared by the cosolvent method, 
extruded, and for which FTIR indicated high PFOB content should be easiest to pellet. In 
contrast, DE emulsion with low PFOB content would not pellet easily. Particle sizes of DE 
and HPL emulsions after extrusion were verified by DLS to be similar (534nm and 548nm). 
FTIR was used to determine the PFOB content of HPL emulsion in pellet and supernatant.
3.4.5 Cryogenic transmission electron microscopy (Cryo-TEM)
To verify the morphology of HPL emulsion made above/below PTT and DE emulsion, 
TEM image were applied. Due to the fragility of the emulsion, Cryo-TEM can prevent 
emulsion from PFOB evaporation and structural rupture. For the samples of DE and HPL 
emulsion (with extrusion), approximately 3.5 ^L of solution was placed on a holey-carbon- 
coated copper grid, blotted, and plunge-frozen in liquid ethane using an FEI Vitrobot 
(Hillsboro). Samples were then transferred to a Gatan 626 cryoholder (Pleasanton) cooled 
with liquid nitrogen. Cryo-TEM images were recorded at 200 kV in an FEI Tecnai F20 
transmission electron microscope (Hillsboro) with the assistance of Dr. David Belnap, who 
helped prepare Cryo-TEM sample pretreatment procedures and acquired images.
3.5 Results and discussion
3.5.1 Miscibility of cosolvent with PFOB 
To determine miscibility of cosolvent and PFOB, 1:1 mixtures of cosolvent/PFOB were 












Figure 3.1 Methanol/PFOB, ethanol/PFOB, chloroform/PFOB, and hexane/PFOB mixtures. 
Methanol and ethanol are not miscible in PFOB so a clear boundary line can be seen in 
those mixtures. Due to higher density of PFOB, the top layer should be methanol and 
ethanol, respectively. Chloroform and hexane are miscible well with PFOB so no obvious 
boundary line can be found in those mixtures.
and ethanol-PFOB phases. Due to the density difference (rmethanol=0.792 g/ml, rethanol=0.789 
g/ml, and rPFOB=1.93 g/ml), the bottom layer is PFOB and the upper one is the cosolvent. It 
can be explained by viewing the dipole moment and polarity index of cosolvents. The 
dipole moment and polarity index of cosolvents could be found in previous reference [446, 
447] (Methanol: 1.7 p, 6.2; Ethanol: 1.69 p, 5.2; Chloroform: 1.04 p, 4.3; Hexane: 0 p, 0). 
The chemical structure of PFOB is relative symmetrical; only bromine atom lies at the end 
of the structure. The electronegativity of bromine (2.96) and chlorine (3.16) is fairly close 
[448]. Hence, PFOB should be classified as a nonpolar solvent. Due to a higher polarity of 




Cosolvents (10 ml)/PFOB(1 ml) mixtures with added 1.0 g of lecithin at 20 °C are 
shown in Figure 3.2. Because PFOB has limited lipid solubility [449], most of the lecithin 
remained in the methanol and ethanol top layers, while a clear layer of PFOB remains in 
the bottom. Lecithin dispersed throughout the chloroform/PFOB mixture, forming a 
uniform transparent solution. Lecithin also dispersed throughout the hexane/PFOB but 
formed a uniform translucent solution.
The above four emulsions were allowed to rest overnight to observe any changes 
(Figure 3.3). Lecithin in the hexane/PFOB solvent separated into two layers, a clear layer 
on the top and a denser white layer on the bottom, while the other had no visible change. 
The clear layer contained hexane (determined by relative density compared to water) and
Figure 3.2 Lecithin dissolved in (a) methanol/PFOB, (b) ethanol/PFOB, (c) 
chloroform/PFOB, and (d) hexane/PFOB mixtures. Lecithin in chloroform/PFOB formed a 





Lecithin in Lecithin in Lecithin in 
Ethanol/PFOB Chloroform/PFOB Hexane/PFOB
Figure 3.3 Four samples were allowed to rest overnight. From left to right: lecithin 
dissolved in methanol/PFOB, ethanol/PFOB, chloroform/PFOB, and hexane/PFOB. Only 
the latter produced a translucent emulsion that settled by gravity over time. The bottom 
layer of lecithin/PFOB/hexane should contain PFOB due to higher density.
some unused lecithin. The volume of the upper clear layer was similar to that of the 
amount of hexane added. Because of PFOB’s higher relative density compared to hexane, 
the lower white layer should contain emulsion of lecithin-encapsulated PFOB. No droplets 
of clear PFOB were seen visibly.
To remove the higher volatility cosolvents and lower volatility unencapsulated PFOB 
from the emulsions, the four samples were dried by vacuum (about 0.25 atm) for 10 hours 
(Figure 3.4). Encapsulated PFOB is expected to be most resistant to vaporization. A light 
yellow solid material was generated in all four samples after the cosolvents were dried out. 
Cosolvent-dissolved lecithin gradually precipitated as cosolvent disappeared. In contrast, 
the sample prepared with hexane formed a uniform white solid (approximate volume: 2~3 
ml) at the bottom of the vial.
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Lecithin in Lecithin in Lecithin in Lecithin in 
Methanol/PFOB Ethanol/PFOB Chloroform/PFOB Hexane/PFOB
Figure 3.4 Samples prepared using the four cosolvents: methanol, ethanol, chloroform, and 
hexane, mixed with PFOB and vacuum-dried for 10 hours.
After the vaccum drying step, 5ml water was added and the suspension stirred at 300 
rpm for 10 min to form a uniform phase. In Figure 3.5, four emulsions (MPL, EPL, CPL, 
and HPL emulsions) are shown after water resuspension.
The FTIR spectra of lecithin in water and PFOB are shown in Figure 3.6. Since PFOB 
shows peaks in the wavenumber range between 1000 to 1500 cm-1, all subsequent scans 
focused on this region. Baseline-corrected FTIR spectra from MPL, EPL, CPL, and HPL 
emulsions (obtained by subtracting the spectra of lecithin in water from that of each sample 
and multiplying each by 20) are shown in the inset of Figure 3.7(a). MPL and EPL 
emulsions have no obvious peaks between the C-F bonds because almost all PFOB 
evaporated during vacuum. CPL emulsion had a small amount of PFOB retained and HPL 
the most. The absorbance at 1188 cm-1 versus polarity index in Figure 3.7(b) shows the 
PFOB retain rate has linear relation to the polarity index of the cosolvents. If the polarity
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Lecithin in Lecithin in Lecithin in Lecithin in 
Methanol/PFOB Ethanol/PFOB Chloroform/PFOB Hexane/PFOB 
(MPL emulsion) (EPL emulsion) (CPL emulsion) (HPL emulsion)
Figure 3.5 Water was added into each of the vacuum-dried samples. From left to right: 
lecithin dissolved in methanol/PFOB (MPL emulsion), ethanol/PFOB (EPL emulsion), 
chloroform/PFOB (CPL emulsion), and hexane/PFOB (HPL emulsion). It is difficult to tell 
the structure difference (liposome or emulsion) of these four samples so FTIR was applied 
to verify if PFOB was present after vacuuming.
Lecithin in water 
PFOB
Wavenumbers (cm-1)
Figure 3.6 The FTIR spectra of lecithin in water and PFOB. Due to more than two fluorine 
atoms in the molecular structure of PFOB, the C-F strong peak would split into two peaks 
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Figure 3.7 FTIR spectra of cosolvent and the curve of absorbance versus polarity index. (a) 
The FTIR spectra of MPL, EPL, CPL, and HPL emulsions. HPL retained the largest 
amount of PFOB. CPL emulsion only retained a small amount of PFOB but MPL and EPL 
emulsion shows no PFOB retained. (b) The curve of the absorbance at 1188 cm-1 versus 
polarity index shows PFOB retain rate has linear relation to polarity index. It shows that 
the polarity index of cosolvent is close to the polarity index of PFOB and can retain more 
PFOB during the new PFOB emulsion synthesis method.
index of cosolvent is close to the polarity index of PFOB, more PFOB can be retained. 
Quantitative evaluation of the amount retain is described later.
A standard curve of baseline-corrected FT-IR peak intensity at 1242 cm-1 
corresponding to PFOB versus wt% of PFOB in hexane mixture was constructed in order 
to estimate the % of PFOB retained in the emulsion by this procedure (Table 3.3). 
Baselines were fitted by drawing a straight line across the two lowest sides of the peak (i.e., 
bottom) and subtracting. A trendline y= 5.7265x -  0.3851 with R2 value of 0.98 was 
obtained. It can be found that the HPL emulsion has 72.0% PFOB retain rate by the 
cosolvent method.
3.5.3 Phase transition temperature (PTT)
To determine if temperature could be manipulated to increase the encapsulation 
efficiency for PFOB, HPL emulsions were prepared at several temperatures between 0 °C 


















Table 3.3 The standard FT-IR samples: Various ratios of hexane to PFOB (DPFoB= 
1.93g/ml and Dhexane 0.66g/ml).
Volume ratio: Weight ratio: PFOB weight portion:
PFOB/Hexane PFOB/Hexane PFOB/total weight
50PF OB/50Hexane 50/50 96.5/32.7 0.747
30PFOB/70Hexane 30/70 57.9/45.8 0.558
20PFOB/80Hexane 20/80 38.6/52.4 0.424
10PFOB/90Hexane 10/90 19.3/58.9 0.247
vacuum drying had a different appearance depending on the temperature at which it was 
prepared. Below 24 oC, the mixture is translucent and above it, transparent. This transition 
point is easily shown by monitoring the UV-Vis spectrum at 525 nm as a function of 
temperature (Figure 3.8). It is also corroborated by DLS measurement, shown in Table 3.4.
To understand the significance of the difference in HPL synthesis between the two 
extremes of temperature, hexane/PFOB mixture at 0 °C and 30 °C were synthesized, 
respectively. After that, both samples were placed in vacuum at 4 °C for 10 hours and 
resuspended by 10 ml E-pure water. FT-IR spectra of these two samples in Figure 3.9 were 
measured after they were vacuumed dried and resuspended by water. For emulsion 
prepared at 30 °C, no PFOB was retained.
3.5.4 Fluorescence
During emulsion synthesis, it is inevitable for extra lipids to form liposomes mixed 
with the emulsion [181, 182]. To distinguish liposomes and emulsions generated by direct-
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Temperature (°C)
Figure 3.8 Phase transition temperate (PTT) of lecithin in PFOB/hexane measurement: 
UV-Vis measurement at 525 nm for lecithin in hexane/PFOB mixture before vacuum 
drying versus temperature. The first transition is between 13 °C and 19 °C, and the second 
around 22 °C to 24 °C.
Table 3.4 The particle size of lecithin in PFOB/hexane at 10 °C, 20 °C, and 30 °C. Because 
the particle size was too small if the applied temperature was 30 °C, the color of emulsion 
would be transparent.




10 344.7 ± 52.33 0.272 White
20 258.6 ± 39.33 0.366 White
30 54.1 ± 0.85 0.220 Transparent
Wavenumbers (cm-1)
Figure 3.9 FT-IR spectra for HPL emulsions synthesized at 0 oC and 30 oC between 1000 
and 1500 cm-1 show explicit details for PFOB bands.
emulsified and cosolvent methods, two added fluorescent dyes, fluorescein and pyrene, 
could be achieved. The relative solubility of fluorescein and pyrene in water and PFOB 
was first determined using fluorescence measurements (Figure 3.10). Fluorescein is 
essentially insoluble in PFOB. Pyrene is highly soluble in PFOB and partially in water. 
However, the spectra of pyrene is different in polar water and non-polar PFOB due to 
solvatochromic behavior [450], and this difference can be used to determine the 
partitioning between the two materials. An extra peak at 381nm of pyrene in PFOB could 
be used to decide where the fluorescence comes from.
Histograms presenting the change of fluorescent intensity at 518 nm for fluorescein and 
394 nm for pyrene as a ratio of initial intensity (I0) (measured before extrusion) to I 
(measured after extrusion) are shown in Figure 3.11. For HPL emulsion, less fluorescein is 
retained in the suspension after dialysis compared with DE emulsion. The large loss in 
fluorescein signal suggests that there are fewer fluorescein-friendly reservoirs (i.e., 








Figure 3.10 Fluorescence spectra. (a) The fluorescence spectra of fluorescein in water and 
PFOB: it shows fluorescein in water has a peak at 518 nm but no fluorescent intensity as 
fluorescein in PFOB. The excitation wavelength was applied for 480 nm. (b) The 
fluorescent spectra of pyrene in water and PFOB: there are three peaks at 372 nm, 381 nm, 









Figure 3.11 The ratio of fluorescent intensity is defined that the denominator is the 
intensity of fluorescein and pyrene in PFOB emulsion before extrusion (I0) and the 
numerator is the intensity of fluorescein and pyrene in PFOB emulsion before extrusion, 
after extrusion but before dialysis, and after dialysis (I). The fluorescent intensity of 
fluorescein and pyrene is decided at 518 nm and 394 nm, respectively. (a) Fluorescent 
intensity ratios of fluorescein and pyrene in PFOB emulsion made by the direct-emulsified 
method. (b) Fluorescent intensity ratios of fluorescein and pyrene in PFOB emulsion made 
by the cosolvent method.
HPL emulsion and the pyrene spectrum reflects entrapment of the dye in a hydrophobic 
compartment.
3.5.5 Centrifugation
As another supporting evidence for the presence of a liposome phase in the extrusion- 
prepared suspension, centrifugation was used to separate the dense fraction in the 
suspension, and DLS used to characterize the supernatant. For suspension containing 
mainly high density PFOB O/W emulsions, the supernatant should have few particulates, 
whereas for a suspension with a mixture of liposome and high density emulsions, the 
supernatant should remain translucent and DLS indicates particulate structures are present. 
After 10 min of centrifugation at room temperature (25 °C) at 2000 rpm, only the HPL 
emulsion separated into two layers, but there is no separation found for DE emulsion. The
ba
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top layer is clear (transparent) and the bottom layer is opaque (white). The particle size of 
the opaque layer right layer by DLS (Fig 3.12(b)) was analyzed and possessed 
approximately 600 nm diameter particles, similar to the situation before centrifugation. 
FTIR analyses of supernatant and pellet also identify the pellet as the PFOB-rich phase in 
Fig 3.13 but not in the supernatant. It can be concluded that our cosolvent produces more 
PFOB emulsion than does the extrusion method.
3.5.6 Cryo-TEM
Two samples of emulsions prepared above and below were imaged in Figure 3.14 and 
3.15. For emulsions made below PTT (Figure 3.14(a) and 3.14(b)), the darker and lighter 
structures are PFOB emulsion and water liposomes, respectively. The darker areas arise 
because PFOB has higher electron density than water. Layered structures and spherical 
emulsion particles of emulsions were also found (Figure 3.14(c)). It indicates that the 
morphology of emulsion could be altered during vacuum, which means round emulsion 
changes to layer-shaped emulsion for higher packing density if cosolvent is removed. From 
size measurement, the polydispersity index (PDI) of HPL emulsion without extrusion gave 
high value around 0.8~0.9 because its morphology has layer-liked structure. The layered 
structure can carry PFOB as seen in Figure 3.14(d). For emulsion made above PTT, there 
are also PFOB emulsions and water liposomes presented in Figure 3.15(b), 3.15(c), and 
3.15(d). Layered structures were also formed in Figure 3.15(a) and 3.15(d). The lighter 
round area in the background is the hole on the carbon-coated copper grid and not part of 
the sample.
Also, the images of two samples, DE emulsion and extruded HPL emulsion in the 
centrifugation section, were obtained in Figure 3.16 and 3.17. It could be found that water
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Figure 3.12 The results of centrifugation. (a) DE and HPL emulsion before centrifugation. 
(b) DE and HPL emulsion after centrifugation (2000 rpm, 10 min). There is a separation 
for HPL emulsion but not for DE emulsion. It shows HPL emulsion has PFOB emulsion 











Figure 3.13 The FTIR spectra of supernatant and pellet of HPL emulsion after 
centrifugation. In the top layer, the spectrum is like only water or lecithin in water (in 
Figure 3.6). In bottom layer, the spectrum shows the peaks from C-F bonds (PFOB 
existence).
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Figure 3.14 Typical cryo-TEM images of emulsions made by mixing 
lecithin/PFOB/hexane at 0 °C (smaller than PTT), vacuum at 4 °C for 10 hours and 
resuspended by water. The darker and lighter structures are PFOB emulsion and water 
liposomes, respectively. Spherical emulsion particles and layered structures were also 
found in Figure 3.14(c) and (d).
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Figure 3.15 TEM images of emulsions made by mixing lecithin/PFOB/hexane at 30°C 
(larger than PTT), vacuum at 4°C for 10 hours and resuspended by water. The darker and 
lighter structures are PFOB emulsion and water liposomes, respectively.
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Figure 3.16 TEM images of DE emulsions: the darker and lighter structures are PFOB 
emulsion and water liposomes, respectively. Only few PFOB emulsions were present and 
most particles in the images were liposomes.
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Figure 3.17 TEM images of HPL emulsion: the darker and lighter structures are PFOB 
emulsion and water liposomes, respectively. Compared to the image of DE emulsion, more 
PFOB emulsions were present in the images.
liposomes are the majority and there are only a few PFOB emulsions in Figure 3.16. 
Compared to Figure 3.17, more PFOB emulsions are made by the cosolvent method. In 
Figure 3.17(a), the layer structure-contained PFOB is also found even after extrusion. 
Identically, the light round background in Figure 3.17 is the hole on the carbon-coated 
copper grid.
3.6 Conclusion
In this study, four cosolvents were tested for their ability to increase the yield of PFOB 
emulsions. By FTIR, it was found that the use of hexane as cosolvent leads to significantly 
higher PFOB retention following vacuum drying. This is thought to be related to the fact 
that hexane dissolves lecithin and mixes with PFOB well. PFOB emulsion formation at 
various temperatures revealed a PTT above which poor PFOB retention was the case. 
Produced materials generally have a high polydispersity with a significantly large 
population of liposome structures. The cosolvent method described here reduces this 
problem and provides a means for producing highly concentrated emulsions. Such 
materials may find use in medicine or biotechnology [11, 214, 451-455] as they have 
excellent ability to dissolve physically significant amounts of oxygen (O2 ) and carbon 
dioxide (CO2) compared to water [456-458]. The technique described is not limited to 1- 




CONCLUSION AND FUTURE RESEARCH
The primary goal of the thesis project was to 1) understand the property and behaviors 
of coating materials assembled by electrostatic forces on the surface of PFOB emulsions, 
and 2) to improve the efficiency of producing uniform PFOB emulsions using a cosolvent 
method. Both these topics have been prepared for peer-reviewed publications.
In Chapter 1, a brief introduction of PFOB emulsion use as artificial blood substitutes 
and the related background of oil-in-water (O/W) systems were reviewed. Additionally, the 
synthesis and coating challenges for PFOB emulsions and the rationale behind material 
selection were discussed.
In the beginning of Chapter 2, a small amount (2%) of DOPA (an ionic surfactant) was 
mixed with lecithin (98%) (a nonionic surfactant) to increase surface charge of PFOB 
emulsions for advantageous electrostatic coating with other materials while permitting only 
minimal increase in production cost. The curves of zeta potential versus pH of the resulting 
2D98L emulsions and lecithin-only emulsions were constructed and the isoelectric point 
identified. In the rest of Chapter 2, construction of polypeptide PLL and polysaccharide 
chitosan coatings on PFOB emulsions were studied in detail. Here is the summary of the 
conclusions:
1. Zeta potential changes versus pH: The relationship between the curves of zeta 
potential of the coating material and the PFOB emulsions was used to identify 
conditions where the coating material and emulsions have opposite electrical charge. 
Because the zeta potential of PLL and chitosan solution without pH titration is 
positive, they can be naturally coated on negatively charged emulsions via 
electrostatic force. The curve shape could be attributed to the phosphate head 
groups of the lipids.
2. Zeta potential, coating concentration, and size of emulsion at pH 7.2: As PLL 
coating concentration increases, zeta potential of coated emulsions becomes less 
negative and the particles tend toward electrical neutrality. Once the surface charge 
reached a critical minimum, as expected, flocculation, as evidenced by the size of 
PLL-coated emulsion, occurred. This effect was reversible. The zeta potential of 
chitosan-coated emulsions also became less negative but never approached 
neutrality so flocculation was avoided.
3. Zeta potential, coating concentration, and size of emulsion at various pH and 
temperature: Using MarvinSketch, the surfactant length and head group size of 
DOPA and lecithin were modeled in order to predict the size of the PFOB core of 
emulsion and the typical 2D98L emulsion concentration was calculated as 68.4 nM. 
From zeta potential measurement, a model relating surface charge density, coating, 
and the calculated emulsion concentration was used to calculate the concentration 
of bound coating materials, and the effective concentration of emulsion particles. 
The discrepancy between colorimetric/zeta potential back calculation of emulsion 
concentration and model calculation suggested a changing effective volume of the
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coating molecules as a function of coating concentration. Using colorimetric and 
zeta potential measurements of the concentration of bound coating materials, a 
compression/expansion ratio (CER) can be defined and related to the conformation 
of molecules in the coating. If CER is smaller than one, it suggests that the coating 
materials have expanded as their accumulation on the emulsion surface progresses 
and vice versa. PLL appears to become more compressed, but chitosan becomes 
more expanded as coating concentration increases.
4. Fluorescent quenching and thermodynamic analysis: To prove the above hypothesis 
of compression/expansion without relying on assumptions inherent in the 
performed calculations, the conformation of PLL and chitosan on emulsions was 
probed by using iodide ions (I-) to quench fluorescent dye pyrene trapped inside 
PFOB emulsion core. PLL exhibiting a compressed conformation had less 
fluorescent quenching than chitosan, consistent with the model. The predicted 
calculation and quenching-indicated conformation result also matched the 
thermodynamic analysis. The Gibbs free energy is lower as the compressed 
conformation of PLL and chitosan molecules on emulsions, which means the 
coating concentration of PLL and chitosan increases and decreases, respectively. 
The expanded conformation has higher free energy than the compressed one.
5. Overall: An easy and convenient method for conformation analysis of coating 
materials on submicron particles such as emulsions was developed. This procedure 
could be used to screen a wide range of coating materials and anticipate their 
conformation-based performance.
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In Chapter 3, a novel method of emulsion production by cosolvent was proposed to 
address problems of side-product liposome formation inherent in emulsion production. 
This problem is most severe in systems where surfactant-oil and surfactant-water solubility 
has not been or cannot be optimized. The cosolvent helps the surfactant (i.e., lecithin) 
disperse with oil (i.e., PFOB) in the absence of water. After a uniform mixture is produced, 
the cosolvent is removed and replaced with water. This method is efficient, and avoids the 
need for lengthy mechanical agitation, extrusion, or homogenization. The emulsion made 
by the cosolvent method was compared to the emulsion made by the direct-emulsified 
method. Here is the summary of the conclusions:
1. Effect of cosolvent selection: Four organic solvents, methanol, ethanol, chloroform 
and hexane, were utilized as the cosolvents for the emulsion production. The 
polarity of cosolvent plays an important role to decide the mixing uniformity of oil 
and surfactant. PFOB retention is known by quantifying the specific C-F band in 
the FTIR spectrum. Hexane was the optimal cosolvent for the production of PFOB 
emulsion.
2. Phase transition temperature (PTT): Mixtures of hexane, surfactant, and PFOB 
possess two phase transitions, one around 13 to 19 °C and another at 22 to 24 °C. 
These were identified by UV-Vis spectrophotometry as a change in the 
translucency of the colorless mixture. Above the second transition temperature 
(24 °C), FTIR indicated little PFOB retention in the synthesized emulsion. Hence, it 
was decided to synthesize PFOB emulsion below the lower PTT (mixed at 0 °C and 
vacuumed at 4 °C) to maximize emulsion yield.
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3. FTIR quantitative measurement: The maximum PFOB retention in the emulsion 
(prepared as 1.5 g lecithin dissolved in 15 ml hexane/ 1 ml PFOB at 0 °C, and 
vacuumed for 10 hours at 4 °C) was 72%.
4. Fluorescence: PFOB emulsions made by the direct-emulsified and the cosolvent 
method were compared, respectively, by adding two fluorescent dyes. Fluorescein 
only dissolves slightly in water but not at all in PFOB. Pyrene shows different 
spectra in water (two peaks) and in PFOB (three peaks). PFOB emulsion with 
fluorescein synthesized by the direct-emulsified method still exhibited significant 
fluorescent intensity after overnight dialysis. This suggests a significant population 
fluorescein encapsulated in water liposomes that are present when the emulsion is 
synthesized by the direct-emulsified method. PFOB emulsion with pyrene 
synthesized by the direct-emulsified method shows most PFOB was still retained 
after extrusion and dialysis. PFOB emulsion synthesized by the cosolvent method 
exhibited much lower fluorescein fluorescent intensity after dialysis, suggested 
significantly fewer liposomes were formed. Pyrene in the same system showed 
localization in PFOB and most of the PFOB was retained after extrusion and 
dialysis.
5. Density of emulsion: The densities of PFOB emulsions made by the two methods 
were compared relatively via centrifugation using 2000 rpm for 10 min. Only 
PFOB emulsion synthesized by the cosolvent method had visible pellet formation 
after centrifugation due to higher content of high density PFOB. The DLS 
diameters of DE and HPL emulsion in each material suspension were 534nm and 
548nm, respectively. The pellet showed PFOB content by FTIR. There was no
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obvious separation into pellet and supernatant for PFOB emulsion made by the 
direct-emulsified method, which suggests most of the sample is water-filled 
liposomes and multilamellar structures. Hence, liposomes could be avoided using 
the cosolvent method compared to the direct-emulsified method.
6. DLS: The cosolvent method provides a uniform emulsion with greatly reduced 
amounts of excess liposomes. The method is fairly simple and cheap because no 
special emulsification mixers/machines and homogenizers are needed. It would 
have a great potential and application for the production of emulsion in food, 
cosmetics and pharmaceutical industry.
For the future research, further confirmation of our model/analysis approach is needed 
as well as extension to other coating molecules. For example, PLL with long chain 
length/high molecular weight and chitosan with short chain length/low molecular weight at 
various pH and ionic strengths can be applied to observe if the observed phenomena is 
related only to chain length, or if the specific molecular structure is also important. In 
previous studies, the molecular conformation has been shown to be controlled by the 
proton concentration [460-462] and overall ionic strength [462-465]. For biomedical 
applications, other types of polypeptides, and polypeptide-sugar hybrids, could be used as a 
coating material. Similar molecules are know to have regulatory and signaling function in 
the body, and may result in the formation of bioactive emulsions for theranostic 
applications [466-469]. The developed analysis method for the conformation prediction 
could also be applied to the conjugation and surface coating of nanoparticles or 
multicomponent thin films like Langmuir-Blodgett films.
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Following up on the cosolvent method, the amount of the surfactant, cosolvent, and oil 
could be adjusted to further reduce unreacted surfactant and to increase PFOB 
retention/eliminate liposome for the optimal recipe. The fluorescence signal of fluorescein 
trapped inside the liposomes formed by the extra surfactants would be reduced and the 
FTIR signal for PFOB increased. In addition, temperature and the vacuum-drying times for 
the mixing of surfactant, PFOB, and cosolvent could be optimized to maximize the 
retention of PFOB. Moreover, submicron size homogenization could be performed before 
vacuum-drying to reduce the size and improve the uniformity of the structures. This would 
have the benefit of avoiding size-homogenization at later stages. A membrane homogenizer 
could be set up in a cold room to keep the mixing of hexane, lecithin, and PFOB below 
PTT. After size homogenization and vacuum-drying, the size of PFOB emulsion can be 
measured to verify if better control over size is obtained.
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